

Untitled

Trying 31060000009999...Open

DIALOG INFORMATION SERVICES

PLEASE LOGON:

\*\*\*\*\* HHHHHHHH SSSSSSS? ### Status: Signing onto Dialog \*\*\*\*\*

ENTER PASSWORD:

\*\*\*\*\* HHHHHHHH SSSSSSS? \*\*\*\*\*

Welcome to DIALOG

### Status: Login successfulDialog level 05.20.01D

Last logoff: 21jan08 13:40:38

Logon file1 22jan08 10:43:23

\*\*\* ANNOUNCEMENTS \*\*\*

\*\*\*

\*\*\*The 2008 EMTREE Thesaurus has been added to EMBASE (Files 72, 73, 772, and 972)

NEW FILES RELEASED

\*\*\*Trademarkscan - South Korea (File 655)

RESUMED UPDATING

\*\*\*File 154 & F155, MEDLINE

\*\*\*File 156, ToxFile

\*\*\*

RELOADS COMPLETED

\*\*\*Files 72 & 73, EMBASE

\*\*\*Files 340, 341 & 942, CLAIMS/U.S. Patents - 2006 reload now online

\*\*\*

NEWS

Chemical Structure Searching now available in Prous Science Drug Data Report (F452), Prous Science Drugs of the Future (F453), IMS R&D Focus (F445/955), Pharmaprojects (F128/928), Beilstein Facts (F390), Derwent Chemistry Resource (F355) and Index Chemicus (File 302).

\*\*\*

>>>For the latest news about Dialog products, services, content<<<  
>>>and events, please visit What's New from Dialog at <<<  
>>><http://www.dialog.com/whatsnew/>. You can find news about<<<  
>>>a specific database by entering HELP NEWS <file number>. <<<

\* \* \*

File 1:ERIC 1965-2007/Nov

(c) format only 2007 Dialog

Set Items Description

-----

Cost is in DialUnits

?

Terminal set to DLINK

? B MEDICINE

>>> 138 is unauthorized

>>>1 of the specified files is not available

22jan08 10:43:42 User294085 Session D165.1

\$0.51 0.145 DialUnits File1

Untitled

\$0.51 Estimated cost File1  
\$0.08 TELNET  
\$0.59 Estimated cost this search  
\$0.59 Estimated total session cost 0.145 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 5:Biosis Previews(R) 1926-2008/Jan W2  
(c) 2008 The Thomson Corporation

File 34:SciSearch(R) Cited Ref Sci 1990-2008/Jan W2  
(c) 2008 The Thomson Corp

File 35:Dissertation Abs Online 1861-2007/Oct  
(c) 2007 ProQuest Info&Learning

File 45:EMCare 2008/Jan W2  
(c) 2008 Elsevier B.V.

File 65:Inside Conferences 1993-2008/Jan 18  
(c) 2008 BLDSC all rts. reserv.

File 71:ELSEVIER BIOBASE 1994-2008/Jan W3  
(c) 2008 Elsevier B.V.

File 73:EMBASE 1974-2008/Jan 21  
(c) 2008 Elsevier B.V.

\*File 73: The 2008 EMTREE Thesaurus has been loaded. Please see  
HELP NEWS 72 for details.

File 91:MANTIS(TM) 1880-2007/Apr  
2001 (c) Action Potential

\*File 91: This database has stopped updating temporarily. Please see  
HELP NEWS 91 for details.

File 98:General Sci Abs 1984-2007/Dec  
(c) 2007 The HW Wilson Co.

File 135:NewsRx Weekly Reports 1995-2008/Jan W2  
(c) 2008 NewsRx

File 144:Pascal 1973-2008/Jan W2  
(c) 2008 INIST/CNRS

File 149:TGG Health&Wellness DB(SM) 1976-2008/Dec W5  
(c) 2008 The Gale Group

File 155:MEDLINE(R) 1950-2008/Jan 18  
(c) format only 2008 Dialog

\*File 155: MEDLINE has resumed updating. Please see HELP NEWS 154  
for details.

File 156:ToxFile 1965-2008/Jan W1  
(c) format only 2008 Dialog

\*File 156: ToxFile has resumed updating with the 2008 MeSH.  
Please see HELP NEWS154 for information.

File 159:Cancerlit 1975-2002/Oct  
(c) format only 2002 Dialog

File 162:Global Health 1983-2008/Dec  
(c) 2008 CAB International

File 164:Allied & Complementary Medicine 1984-2008/Jan  
(c) 2008 BLHCIS

File 172:EMBASE Alert 2008/Dec 31  
(c) 2008 Elsevier B.V.

File 266:FEDRIP 2007/Oct  
Comp & dist by NTIS, Intl Copyright All Rights Res

File 369:New Scientist 1994-2007/Sep W4  
(c) 2007 Reed Business Information Ltd.

Untitled

File 370:Science 1996-1999/Jul W3

(c) 1999 AAAS

\*File 370: This file is closed (no updates). Use File 47 for more current information.

File 399:CA SEARCH(R) 1967-2007/UD=14804

(c) 2008 American Chemical Society

\*File 399: Use is subject to the terms of your user/customer agreement.

IPCR/8 classification codes now searchable as IC=. See HELP NEWSIPCR.

File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec

(c) 2006 The Thomson Corp

File 444:New England Journal of Med. 1985-2008/Nov W4

(c) 2008 Mass. Med. Soc.

File 467:ExtraMED(tm) 2000/Dec

(c) 2001 Informania Ltd.

Set Items Description

? E AU=FEYT, ROLANDO

Ref Items Index-term

E1 2 AU=FEYT, R.  
E2 1 AU=FEYT, R. P.  
E3 0 \*AU=FEYT, ROLANDO  
E4 1 AU=FEYTAND J  
E5 10 AU=FEYTAUD J  
E6 1 AU=FEYTAUD JEAN  
E7 1 AU=FEYTAUD, M. DE  
E8 1 AU=FEYTCHE T  
E9 1 AU=FEYTEN K  
E10 2 AU=FEYTEN M P  
E11 1 AU=FEYTEN MP  
E12 5 AU=FEYTEN, C.

Enter P or PAGE for more

? S E2

S1 1 AU='FEYT, R. P.'

? T S1/3/ALL

1/3/1 (Item 1 from file: 65)

DIALOG(R)File 65:Inside Conferences

(c) 2008 BLDSC all rts. reserv. All rts. reserv.

03897843 INSIDE CONFERENCE ITEM ID: CN040960806

Recombinant TbpA protein from Neisseria meningitidis, folded in vitro,  
binds human transferrin

Feyt, R. P. ; Llerandi, K.

CONFERENCE: International pathogenic Neisseria conference-11th

ABSTRACTS OF THE INTERNATIONAL PATHOGENIC NEISSERIA CONFERENCE , 1998;

11TH P: 321

Paris, EDK, 1998

ISBN: 2842540158

LANGUAGE: English DOCUMENT TYPE: Conference Selected abstracts

CONFERENCE LOCATION: Nice, France 1998; Nov (199811)

? S E1

S2 2 AU='FEYT, R.'

Untitled

? RD

S3 2 RD (unique items)

? T S3/3/ALL

3/3/1 (Item 1 from file: 162)

DIALOG(R)File 162:Global Health

(c) 2008 CAB International. All rts. reserv.

0004583682 CAB Accession Number: 19962004291

Epidemiology of respiratory infections caused by Chlamydia pneumoniae in the Somme region: a serological study of 1700 cases examined between October and December 1993.

Original Title: Epidemiologie des infections respiratoires a Chlamydia pneumoniae dans le departement de la Somme: a propos de 1700 effectuees d;octobre a decembre 1993..

Orfila, J.; Chaigneau, C.; Gommeaux, A.; Sueur, J. M.; Feyt, R.

Biobanque de Picardie, 16, rue Fernel, 80000 Amiens, France.

Bulletin Epidemiologique Hebdomadaire (42): p.186-187

Publication Year: 1995

Language: French Record Type: Citation

Document Type: Journal article

3/3/2 (Item 1 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

138352277 CA: 138(23)352277p JOURNAL

A targeted approach significantly increases the identification rate of patients with undiagnosed haemochromatosis

AUTHOR(S): Cadet, E.; Capron, D.; Perez, A. S.; Crepin, S. N.; Arlot, S.;

Ducroix, J.-P.; Dautreux, M.; Fardellone, P.; Leflon, P.;

Merryweather-Clarke, A. T.; Livesey, K. J.; Pointon, J. J.; Rose, P.;

Harcourt, J.; Emery, J.; Sueur, J. M.; Feyt, R.; Robson, K. J. H.;

Rochette, J.

LOCATION: Services de Genetique Medicale, CHU d'Amiens, Faculte de Medecine & Universite Jules Verne de Picardie, 80036, Amiens, Fr.

JOURNAL: J. Intern. Med. (Journal of Internal Medicine) DATE: 2003

VOLUME: 253 NUMBER: 2 PAGES: 217-224 CODEN: JINMEO ISSN: 0954-6820

LANGUAGE: English PUBLISHER: Blackwell Publishing Ltd.

? E AU=NIETO, GERARDO

Ref Items Index-term

E1 2 AU=NIETO, G.

E2 1 AU=NIETO, GEMA

E3 0 \*AU=NIETO, GERARDO

E4 1 AU=NIETO, GERARDO GUILLEN

E5 1 AU=NIETO, GUADALUPE PEREZ-OLIVARES

E6 2 AU=NIETO, H.

E7 6 AU=NIETO, I.

E8 1 AU=NIETO, I. G. DE

E9 2 AU=NIETO, IGNACIO

E10 3 AU=NIETO, INES

E11 1 AU=NIETO, IRIS

E12 5 AU=NIETO, ISABEL

Untitled

Enter P or PAGE for more

? S E1 OR E4

2 AU=NIETO, G.

1 AU=NIETO, GERARDO GUILLEN

S4 3 AU='NIETO, G.' OR AU='NIETO, GERARDO GUILLEN'

? RD

S5 3 RD (unique items)

? T S5/3/ALL

5/3/1 (Item 1 from file: 65)

DIALOG(R)File 65:Inside Conferences

(c) 2008 BLDSC all rts. reserv. All rts. reserv.

04726159 INSIDE CONFERENCE ITEM ID: CN049348551

The Chinese in Spain

Nieto, G.

CONFERENCE: Understanding migration between China and Europe-Expert meeting

INTERNATIONAL MIGRATION -GENEVA THEN OXFORD-, 2003; VOL 41; NO 3; SPEC.

ISSUE 1 P: 215-238

Blackwell Publishing, 2003

ISSN: 0020-7985

LANGUAGE: English DOCUMENT TYPE: Conference Papers

CONFERENCE EDITOR(S): Laczko, F.

CONFERENCE SPONSOR: International Organization for Migration

CONFERENCE LOCATION: Madrid 2002; Jun (200206)

NOTE:

Held in conjunction with expert meeting: Understanding migration between China and Europe held in October 2002 in Brussels

5/3/2 (Item 1 from file: 162)

DIALOG(R)File 162:Global Health

(c) 2008 CAB International. All rts. reserv.

0005000987 CAB Accession Number: 20043128885

Association between AIDS disease progression rates and the Fok -I polymorphism of the VDR gene in a cohort of HIV-1 seropositive patients.

Nieto, G.; Barber, Y.; Rubio, M. C.; Rubio, M.; Fibla, J.

Author email address: joan.fibla@cmb.udl.es

Unitat de Genetica Humana del Departament de Ciencies Mediques Basiques  
de la Facultat de Medicina de la Universitat de Lleida, C/Montserrat Roig  
2, 25199 Lleida, Catalunya, Spain.

Conference Title: Proceedings of the 12th Workshop on Vitamin D,  
Maastricht, The Netherlands, 6-10 July 2003.

Journal of Steroid Biochemistry and Molecular Biology vol. 89/90 (1/5):  
p.199-207

Publication Year: 2004

ISSN: 0960-0760

Editors: Bouillon, R.; Norman, A. W.; Pasqualini, J. R.

Publisher: Elsevier Science Ltd Oxford, UK

Language: English Record Type: Abstract

Document Type: Journal article; Conference paper

Untitled

5/3/3 (Item 1 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

131063365 CA: 131(5)63365s JOURNAL  
Preformulation study of the vaccine candidate P64k against Neisseria  
meningitidis  
AUTHOR(S): Raya, Nestor Exposito; Luaces, Marissa Mestre; Rodriguez,  
Ricardo Silva; Galvez, Consuelo Nazabal; Rivero, Maxlenin Pena; De la  
Puente, Nieves Martinez; Batista, Milagros Font; Nieto, Gerardo Guillen  
LOCATION: Division de Formulacion y Envase, Centro de Ingenieria Genetica  
y Biotecnologia, Havana, Cuba, 10600  
JOURNAL: Biotechnol. Appl. Biochem. DATE: 1999 VOLUME: 29 NUMBER: 2  
PAGES: 113-117 CODEN: BABIEC ISSN: 0885-4513 LANGUAGE: English  
PUBLISHER: Portland Press Ltd.  
? E AU=GARCIA, GRETEL

Ref Items Index-term  
E1 3 AU=GARCIA, GRETCHEN  
E2 5 AU=GARCIA, GRETCHEN E.  
E3 0 \*AU=GARCIA, GRETEL  
E4 4 AU=GARCIA, GRISELDA  
E5 4 AU=GARCIA, GUADALUPE  
E6 1 AU=GARCIA, GUIDO  
E7 1 AU=GARCIA, GUILHERME DE ANDRADE  
E8 6 AU=GARCIA, GUILHERME J. M.  
E9 2 AU=GARCIA, GUILLAUME  
E10 4 AU=GARCIA, GUILLERMINA  
E11 10 AU=GARCIA, GUILLERMINA C.  
E12 5 AU=GARCIA, GUILLERMO

Enter P or PAGE for more  
? E AU=NUNEZ LAZARO

Ref Items Index-term  
E1 0 \*AU=NUNEZ LAZARO  
E2 1 AU=NUNEZ LAZARO HIRAM BETANCOURT  
E3 1 AU=NUNEZ LAZO, FEDERICO  
E4 1 AU=NUNEZ LC  
E5 8 AU=NUNEZ LE  
E6 2 AU=NUNEZ LEANDRO V  
E7 1 AU=NUNEZ LEON F.  
E8 1 AU=NUNEZ LEOPOLDO  
E9 1 AU=NUNEZ LEOS J J  
E10 1 AU=NUNEZ LEOS JUAN JOSE  
E11 2 AU=NUNEZ LEZAMA L  
E12 4 AU=NUNEZ LH

Enter P or PAGE for more  
? S E2  
S6 1 AU=NUNEZ LAZARO HIRAM BETANCOURT  
? T S6/3/ALL

6/3/1 (Item 1 from file: 5)

Untitled

DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

0019950107 BIOSIS NO.: 200700609848

Method of selective peptide isolation for the identification and  
quantitative analysis of proteins in complex mixtures

AUTHOR: Anonymous; Nunez Lazaro Hiram Betancourt ; de Cossio Dorta-Duque  
Jorge Fernandez; Perez Vladimir Armando Besada; Valdes Jeovanis Gil;  
Lopez Luis Javier Gonzalez; Palomares Gabriel Ramon Padron; Feyt Rolando  
Pajon; Gil Felix Modesto Alvarez

AUTHOR ADDRESS: Havana, Cuba\*\*Cuba

JOURNAL: Official Gazette of the United States Patent and Trademark Office

Patents JUL 17 2007 2007

PATENT NUMBER: US 07244411 PATENT DATE GRANTED: July 17, 2007 20070717

PATENT CLASSIFICATION: 424-169 PATENT ASSIGNEE: Centro de Ingenieria  
Genetica y Biotecnologia PATENT COUNTRY: USA

ISSN: 0098-1133

DOCUMENT TYPE: Patent

RECORD TYPE: Abstract

LANGUAGE: English

? E AU=SERRA, LILA

Ref Items Index-term

E1 0 \*AU=SERRA, LILA  
E2 2 AU=SERRA, LL  
E3 23 AU=SERRA, LL.  
E4 52 AU=SERRA, LLORENC  
E5 1 AU=SERRA, LLORENQ  
E6 1 AU=SERRA, LLU S  
E7 1 AU=SERRA, LLUIS  
E8 1 AU=SERRA, LU S  
E9 1 AU=SERRA, LU<S  
E10 2 AU=SERRA, LUCA  
E11 1 AU=SERRA, LUCIANO R.  
E12 1 AU=SERRA, LUIGI

Enter P or PAGE for more

? E AU= NEGRIN, YASSER

Ref Items Index-term

E1 1 AU=NEGRIN, ROBERT S. M. D.  
E2 4 AU=NEGRIN, S.  
E3 0 \*AU=NEGRIN, YASSER  
E4 2 AU=NEGRIN, ZENAIDA RODRIGUEZ  
E5 10 AU=NEGRINE J  
E6 1 AU=NEGRINE J P  
E7 4 AU=NEGRINE J.  
E8 10 AU=NEGRINE J.P.  
E9 1 AU=NEGRINE JOHN  
E10 5 AU=NEGRINE JOHN P  
E11 5 AU=NEGRINE JP  
E12 3 AU=NEGRINE R.J.S.

Enter P or PAGE for more

? E AU=DIAZ, DARIEN

Untitled

Ref Items Index-term

- E1 1 AU=DIAZ, DANILO V.
- E2 0 \*AU=DIAZ, DARIEN
- E3 38 AU=DIAZ, DAVID
- E4 3 AU=DIAZ, DAVID D
- E5 30 AU=DIAZ, DAVID D.
- E6 1 AU=DIAZ, DAVID DEMETRIO
- E7 5 AU=DIAZ, DAVID DIAZ
- E8 1 AU=DIAZ, DAVID G.
- E9 14 AU=DIAZ, DAVID J (ED)
- E10 6 AU=DIAZ, DAVID J.
- E11 1 AU=DIAZ, DAVID RALPH
- E12 1 AU=DIAZ, DAVID SABINA

Enter P or PAGE for more

? E AU=PEREZ, OLIVIA

Ref Items Index-term

- E1 23 AU=PEREZ, OLIVER
- E2 2 AU=PEREZ, OLIVER A.
- E3 0 \*AU=PEREZ, OLIVIA
- E4 8 AU=PEREZ, OLIVIER
- E5 14 AU=PEREZ, OMAR
- E6 1 AU=PEREZ, OMAR D
- E7 19 AU=PEREZ, OMAR D.
- E8 2 AU=PEREZ, OMAR DAVID
- E9 1 AU=PEREZ, OMAR J.
- E10 15 AU=PEREZ, ONESIMA
- E11 8 AU=PEREZ, ORLANDO
- E12 3 AU=PEREZ, ORLANDO A.

Enter P or PAGE for more

? E AU=MENEDEZ,EVELIN

Ref Items Index-term

- E1 3 AU=MENEDEZ, S.
- E2 1 AU=MENEDEZ, VICENTE
- E3 0 \*AU=MENEDEZ,EVELIN
- E4 1 AU=MENEDEZARIAS L
- E5 1 AU=MENEDEZBARRETO M
- E6 1 AU=MENEDEZBOTET C
- E7 1 AU=MENEDEZPATTERSON A
- E8 1 AU=MENEDEZVELAZQUEZ A
- E9 1 AU=MENEDIAN R V
- E10 1 AU=MENEDNDEZ CARLOS
- E11 1 AU=MENEDZ CARMEN
- E12 2 AU=MENEIH I S

Enter P or PAGE for more

? E AU=BLANCO, SONIA

Ref Items Index-term

- E1 13 AU=BLANCO, SOFIA T.
- E2 4 \*AU=BLANCO, SONIA

Untitled

E3 15 AU=BLANCO, SONIA E.  
E4 2 AU=BLANCO, SONIA ENCARNACION  
E5 1 AU=BLANCO, SONIA LUCIA  
E6 2 AU=BLANCO, STANLEY  
E7 1 AU=BLANCO, STELLA  
E8 3 AU=BLANCO, STEPHANE  
E9 46 AU=BLANCO, SUSANA  
E10 2 AU=BLANCO, T.  
E11 1 AU=BLANCO, T. A.  
E12 1 AU=BLANCO, T. B.

Enter P or PAGE for more

? S E2 OR E3  
4 AU=BLANCO, SONIA  
15 AU=BLANCO, SONIA E.  
S7 19 AU='BLANCO, SONIA' OR AU='BLANCO, SONIA E.'

? RD  
S8 19 RD (unique items)  
? S NEISSERIA  
S9 103921 NEISSERIA  
? S S7 AND S9  
19 S7  
103921 S9  
S10 0 S7 AND S9

? T S7/E/ALL  
>>>'E' not a valid format name  
? T S8/3/ALL

8/3/1 (Item 1 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

147072416 CA: 147(4)72416s JOURNAL  
Solvation of monoacidic conjugate bases and calculation of acidity  
constants in aqueous solutions  
AUTHOR(S): Blanco, Sonia E.; Ferretti, Ferdinando H.  
LOCATION: Argent.  
JOURNAL: Phys. Chem. (Rajkot, India) (Physical Chemistry (Rajkot, India))  
DATE: 2006 VOLUME: 1 NUMBER: 2-3 PAGES: 83-89 CODEN: PCRIBJ  
LANGUAGE: English PUBLISHER: Trade Science Inc.

8/3/2 (Item 2 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

146481716 CA: 146(24)481716v JOURNAL  
Solvent and substituent effects on the conformational equilibria and  
intramolecular hydrogen bonding of 4-substituted-2-hydroxybenzaldehydes  
AUTHOR(S): Blanco, Sonia E.; Ferretti, Ferdinando H.  
LOCATION: Area de Quimica-Fisica, Facultad de Quimica, Bioquimica y  
Farmacia, Universidad Nacional de San Luis, Chacabuco y Pedernera, 5700,  
San Luis, Argent.  
JOURNAL: Tetrahedron Lett. (Tetrahedron Letters) DATE: 2007 VOLUME: 48  
NUMBER: 14 PAGES: 2577-2581 CODEN: TELEAY ISSN: 0040-4039

Untitled

PUBLISHER ITEM IDENTIFIER: 0040-4039(07)00264-X LANGUAGE: English  
PUBLISHER: Elsevier Ltd.

8/3/3 (Item 3 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

146075242 CA: 146(5)75242x JOURNAL  
Determinants of the clinical expression of amoxicillin-clavulanate  
hepatotoxicity: a prospective series from Spain  
CORPORATE AUTHOR(S): The Spanish Group for the Study of Drug-Induced  
Liver Disease Grupo de Estudio para las Hepatopatias Asociadas a  
Medicamentos GEHAM  
AUTHOR(S): Lucena, M. Isabel; Andrade, Raul J.; Fernandez, M. Carmen;  
Pachkoria, Ketevan; Pelaez, Gloria; Duran, Jose A.; Villar, Macarena;  
Rodrigo, Luis; Romero-Gomez, Manuel; Planas, Ramon; Barriocanal, Anabel;  
Costa, Joan; Guarner, Carlos; Blanco, Sonia; Navarro, Jose M.; Pons,  
Fernando; Castiella, Agustin; Avila, Susana  
LOCATION: Servicio de Farmacologia Clinica, Grupo de Estudio para las  
Hepatopatias Asociadas a Medicamentos, Coordinating Centre, Facultad de  
Medicina, Hospital Universitario Virgen de la Victoria, Malaga, Spain,  
JOURNAL: Hepatology (Hoboken, NJ, U. S.) (Hepatology (Hoboken, NJ, United  
States)) DATE: 2006 VOLUME: 44 NUMBER: 4 PAGES: 850-856 CODEN: HPTLD9  
ISSN: 0270-9139 LANGUAGE: English PUBLISHER: John Wiley & Sons, Inc.

8/3/4 (Item 4 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

144168733 CA: 144(10)168733g JOURNAL  
Frequency and clinical expression of HFE gene mutations in a Spanish  
population of subjects with abnormal iron metabolism  
AUTHOR(S): Gomez-Llorente, Carolina; Miranda-Leon, M. Teresa; Blanco,  
Sonia; Gandia-Pla, Sandra; Gomez-Capilla, Jose Antonio; Farez-Vidal, M.  
Esther  
LOCATION: Departamento de Bioquimica y Biologia Molecular, Universidad de  
Granada, Granada, Spain,  
JOURNAL: Ann. Hematol. (Annals of Hematology) DATE: 2005 VOLUME: 84  
NUMBER: 10 PAGES: 650-655 CODEN: ANHEE8 ISSN: 0939-5555 LANGUAGE:  
English PUBLISHER: Springer

8/3/5 (Item 5 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

143168572 CA: 143(10)168572h JOURNAL  
Inhibition of xanthine-oxidase by 2,4-dihydroxybenzophenone and  
2,3,4-trihydroxy-benzophenone  
AUTHOR(S): Castro, Gabriela T.; Blanco, Sonia E.; Ferretti, Fernando H.  
LOCATION: Area d-Quimica-Fisica, Faculty de Quimica, Bioquimica y  
Farmacia, Chacabuco y Pedernera, Universidad Nacional de San Luis, 5700,  
San Luis, Argent.

Untitled

JOURNAL: Internet Electron. J. Mol. Des. (Internet Electronic Journal of Molecular Design) DATE: 2004 VOLUME: 3 NUMBER: 11 PAGES: 684-703  
CODEN: IEJMAT UNIFORM RESOURCE LOCATOR (URL):  
<ftp://biochempress.com/ie-jmd/2004/3/0684.pdf> MEDIA TYPE: online computer file  
ISSN: 1538-6414 LANGUAGE: English PUBLISHER: BioChem Press

8/3/6 (Item 6 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

142316403 CA: 142(17)316403a JOURNAL  
Calculation of acidity constants of pyridines in aqueous solution  
AUTHOR(S): Blanco, Sonia E.; Ferretti, Ferdinando H.  
LOCATION: Area de Quimica - Fisica, Facultad de Quimica, Bioquimica y Farmacia, Universidad Nacional de San Luis, 5700, San Luis, Argent.  
JOURNAL: Chem. Phys. Lett. (Chemical Physics Letters) DATE: 2005  
VOLUME: 403 NUMBER: 4-6 PAGES: 400-404 CODEN: CHPLBC ISSN: 0009-2614  
PUBLISHER ITEM IDENTIFIER: 0009-2614(05)00073-4 LANGUAGE: English  
PUBLISHER: Elsevier B.V.

8/3/7 (Item 7 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

142004936 CA: 142(1)4936h JOURNAL  
Multimutational analysis of eleven cystic fibrosis mutations common in the Mediterranean areas  
AUTHOR(S): Farez-Vidal, M. Esther; Gomez-Llorente, Carolina; Blanco, Sonia; Morales, Pablo; Casals, Teresa; Gomez-Capilla, Jose Antonio  
LOCATION: Servicio de Bioquimica, Hospital Universitario San Cecilio, Granada, Spain,  
JOURNAL: Clin. Chem. (Washington, DC, U. S.) (Clinical Chemistry (Washington, DC, United States)) DATE: 2004 VOLUME: 50 NUMBER: 11  
PAGES: 2155-2157 CODEN: CLCHAU ISSN: 0009-9147 LANGUAGE: English  
PUBLISHER: American Association for Clinical Chemistry

8/3/8 (Item 8 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

141349691 CA: 141(21)349691a JOURNAL  
The effects of substituents and solvents on the conformation of benzophenones  
AUTHOR(S): Mantas, Athena; Blanco, Sonia E.; Ferretti, Ferdinando H.  
LOCATION: Department of Chemistry, University of Toronto, Toronto, ON, Can., M5S 3H6  
JOURNAL: Internet Electron. J. Mol. Des. (Internet Electronic Journal of Molecular Design) DATE: 2004 VOLUME: 3 NUMBER: 7 PAGES: 387-399  
CODEN: IEJMAT UNIFORM RESOURCE LOCATOR (URL):  
<ftp://biochempress.com/iejmd/2004/3/0387.pdf> MEDIA TYPE: online computer file  
ISSN: 1538-6414 LANGUAGE: English PUBLISHER: BioChem Press

Untitled

8/3/9 (Item 9 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

141023035 CA: 141(2)23035j JOURNAL

Structure and dipole moment of catechol in hydroxylic solvents

AUTHOR(S): Rudyk, Roxana A.; Molina, Maria A. A.; Gomez, Maria I.;

Blanco, Sonia E.; Ferretti, Ferdinando H.

LOCATION: Catedra de Quimica General, Facultad de Bioquimica, Universidad Nacional de Tucuman, 4000, Tucuman, Argent.

JOURNAL: Internet Electron. J. Mol. Des. (Internet Electronic Journal of Molecular Design) DATE: 2004 VOLUME: 3 NUMBER: 1 PAGES: 11-28 CODEN: IEJMAT UNIFORM RESOURCE LOCATOR (URL): <http://www.biochempress.com/av030011.html> MEDIA TYPE: online computer file ISSN: 1538-6414 LANGUAGE: English PUBLISHER: BioChem Press

8/3/10 (Item 10 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

140386579 CA: 140(24)386579v JOURNAL

Multiplex analysis of the most common mutations related to hereditary haemochromatosis: two methods combining specific amplification with capillary electrophoresis

AUTHOR(S): Gomez-Llorente, Carolina; Antunez, Adelaida; Blanco, Sonia; Suarez, Antonio; Gomez-Capilla, Jose Antonio; Farez-Vidal, M. Esther

LOCATION: Departamento de Bioquimica y Biologia Molecular, Universidad de Granada, Granada, Spain,

JOURNAL: Eur. J. Haematol. (European Journal of Haematology) DATE: 2004 VOLUME: 72 NUMBER: 2 PAGES: 121-129 CODEN: EJHAEC ISSN: 0902-4441

LANGUAGE: English PUBLISHER: Blackwell Publishing Ltd.

8/3/11 (Item 11 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

133222123 CA: 133(16)222123w JOURNAL

Teaching thermodynamics with simple experiments

AUTHOR(S): Castro, Gabriela T.; Blanco, Sonia E.; Ferretti, Ferdinando H.

LOCATION: Area de Fis., Fac. Quim., Bioquimica Farmacia, Univ. Nacional de San Luis, 5700, San Luis, Argent.

JOURNAL: An. Asoc. Quim. Argent. DATE: 1999 VOLUME: 87 NUMBER: 5-6 PAGES: 219-224 CODEN: AAQAAE ISSN: 0365-0375 LANGUAGE: English

PUBLISHER: Asociacion Quimica Argentina

8/3/12 (Item 12 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

132092997 CA: 132(8)92997a JOURNAL

Variation of 4-hydroxychalcone and 3-hydroxyflavone pKa with solvent

Untitled

permittivity

AUTHOR(S): Gasull, Estela I.; Blanco, Sonia E.; Ferretti, Ferdinando H.  
LOCATION: Area de Quimica-Fisica, Facultad de Quimica, Bioquimica y  
Farmacia, Universidad Nacional de San Luis, 5700, San Luis, Argent.  
JOURNAL: An. Asoc. Quim. Argent. DATE: 1999 VOLUME: 87 NUMBER: 1-2  
PAGES: 73-82 CODEN: AAQAAE ISSN: 0365-0375 LANGUAGE: English  
PUBLISHER: Asociacion Quimica Argentina

8/3/13 (Item 13 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

128257152 CA: 128(21)257152d JOURNAL

Determination of absorptivity and formation constant of a chalcone  
association complex

AUTHOR(S): Blanco, Sonia E.; Ferretti, Ferdinando H.  
LOCATION: Departamento de Quimica, Facultad de Quimica, Bioquimica y  
Farmacia, Universidad Nacional de San Luis, Chacabuco y Pedernera, 5700,  
San Luis, Argent.  
JOURNAL: Talanta DATE: 1998 VOLUME: 45 NUMBER: 6 PAGES: 1103-1109  
CODEN: TLNTA2 ISSN: 0039-9140 LANGUAGE: English PUBLISHER: Elsevier  
Science B.V.

8/3/14 (Item 14 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

125086351 CA: 125(7)86351z JOURNAL

Adsorption of simple flavonoids: heterogeneous isomerization of flavanone  
in 2'-hydroxychalcone

AUTHOR(S): Blanco, Sonia E.; Silber, Juana J.; Narda, Griselda E.; Yamin,  
Lazaro J.; Ferretti, Ferdinando H.  
LOCATION: Laboratorio de Fisicoquimica, Univ. Nacional de San Luis, 5700,  
San Luis, Argent.

JOURNAL: J. Colloid Interface Sci. DATE: 1996 VOLUME: 180 NUMBER: 1  
PAGES: 144-148 CODEN: JCISA5 ISSN: 0021-9797 LANGUAGE: English

8/3/15 (Item 15 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

122178179 CA: 122(15)178179r JOURNAL

Some considerations on receptor kinetics

AUTHOR(S): Assef, Susana B. Garcia; Fuentes, Lucia B.; Blanco, Sonia E.;  
Ferretti, Ferdinando H.  
LOCATION: Fac. de Qca., Bioqca. y Farmacia, U.N. de San Luis, 5700, San  
Luis, Argent.  
JOURNAL: Comun. Biol. DATE: 1994 VOLUME: 12 NUMBER: 1 PAGES: 29-41  
CODEN: COBIEJ ISSN: 0326-1956 LANGUAGE: English

8/3/16 (Item 16 from file: 399)

Untitled

DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

122127365 CA: 122(11)127365r JOURNAL  
Alternative application of the Michaelis and Menten equation on  
enzyme-catalyzed reaction analysis  
AUTHOR(S): Ponce, Ana M.; Molina, Alicia S.; Aragon, Leslie M.; Blanco,  
Sonia E.; Ferretti, Ferdinando H.  
LOCATION: Fac. de Qca., Bioqca. y Farmacia, U.N., 5700, San Luis, Argent.  
JOURNAL: Comun. Biol. DATE: 1993 VOLUME: 11 NUMBER: 4 PAGES: 321-35  
CODEN: COBIEJ ISSN: 0326-1956 LANGUAGE: English

8/3/17 (Item 17 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

121213087 CA: 121(18)213087n JOURNAL  
Noscapine and morphine mixture resolution by UV/visible spectrometry  
AUTHOR(S): Micalizzi, Yolanda C.; Blanco, Sonia E.; Ortega, Claudia;  
Chico, Maria; Salmeron, Susana A.; Ferretti, Ferdinando H.  
LOCATION: Fac. Quim., Bioquimica Farm., Univ. Nacional San Luis, 5700,  
San Luis, Argent.  
JOURNAL: Acta Farm. Bonaerense DATE: 1993 VOLUME: 12 NUMBER: 2  
PAGES: 61-7 CODEN: AFBODJ ISSN: 0326-2383 LANGUAGE: Spanish

8/3/18 (Item 18 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

121042861 CA: 121(4)42861d JOURNAL  
Spectroscopic resolution of mixtures of sulfamethoxazole and trimethoprim  
AUTHOR(S): Blanco, Sonia E.; Ascheri de Salmeron, S.; Casali de  
Micalizzi, Y.; Ferretti, Ferdinando H.  
LOCATION: Fac. de Quim. Bioquim. y Farm., U.N. de San Luis, 5700, SAN  
LUIS, Argent.  
JOURNAL: SAFYBI DATE: 1993 VOLUME: 33 NUMBER: 89 PAGES: 18-25  
CODEN: SAFYAP ISSN: 0558-1265 LANGUAGE: Spanish

8/3/19 (Item 19 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

119270513 CA: 119(25)270513f JOURNAL  
Kinetic determination of pKa in 2'-hydroxychalcones  
AUTHOR(S): Blanco, Sonia E.; Debattista, Nora B.; Luco, Juan M.;  
Ferretti, Ferdinando H.  
LOCATION: Dep. Chem., San Luis Natl. Univ., 5700, San Luis, Argent.  
JOURNAL: Tetrahedron Lett. DATE: 1993 VOLUME: 34 NUMBER: 29 PAGES:  
4615-18 CODEN: TELEAY ISSN: 0040-4039 LANGUAGE: English  
? DS

Set Items Description

Untitled

S1 1 AU='FEYTT, R. P.'  
S2 2 AU='FEYTT, R.'  
S3 2 RD (unique items)  
S4 3 AU='NIETO, G.' OR AU='NIETO, GERARDO GUILLEN'  
S5 3 RD (unique items)  
S6 1 AU='NUNEZ LAZARO HIRAM BETANCOURT'  
S7 19 AU='BLANCO, SONIA' OR AU='BLANCO, SONIA E.'  
S8 19 RD (unique items)  
S9 103921 NEISSERIA  
S10 0 S7 AND S9  
? S PREVENT OR PREVENTION  
    1044952 PREVENT  
    3039672 PREVENTION  
    S11 3855735 PREVENT OR PREVENTION  
? S S9 AND S11  
    103921 S9  
    3855735 S11  
    S12 9266 S9 AND S11  
? S VACCINE  
    S13 710632 VACCINE  
? S S12 AND S13  
    9266 S12  
    710632 S13  
    S14 3715 S12 AND S13  
? S S14 AND REVIEW  
    3715 S14  
    6322183 REVIEW  
    S15 735 S14 AND REVIEW  
? RD  
    S16 593 RD (unique items)  
? S S16 NOT PY>2003  
>>>One or more prefixes are unsupported  
>>> or undefined in one or more files.  
Processing  
Processed 20 of 25 files ...  
Completed processing all files  
    593 S16  
    23784133 PY>2003  
    S17 306 S16 NOT PY>2003  
? T S17/K/1-10  
>>>KWIC option is not available in file(s): 399

17/K/1 (Item 1 from file: 5)  
DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

...ABSTRACT: continue to have a major public health impact in many countries. Five major groups of Neisseria meningitidis (A, B, C, Y and W135) are responsible for most meningococcal diseases. Plain polysaccharides vaccines for Neisseria meningitidis groups A, C, Y and W-135 have been in use for approximately 20 years, both to prevent invasive disease in high-risk population and to control disease outbreaks. However, these conventional meningococcal...

...which offer solid advantages over the currently licensed plain polysaccharide vaccines. There is still no vaccine available against

Untitled

the serogroup B, which is a major cause of invasive disease. This report

...  
**DESCRIPTORS:**

ORGANISMS: Neisseria meningitidis (Neisseriaceae...)

CHEMICALS & BIOCHEMICALS: meningococcal disease vaccine --...

... vaccine , development

**MISCELLANEOUS TERMS:** ...Literature Review

17/K/2 (Item 2 from file: 5)

DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

...ABSTRACT: and advances in bioinformatics have revolutionized the  
vaccinology field, leading to the identification of potential vaccine  
candidates without the need for cultivating the pathogen. This approach,  
termed 'reverse vaccinology', reduces the...

...identification of novel antigens of meningococcus B as potential  
candidates for a novel and effective vaccine . The same approach has  
been successfully applied to other important human pathogens,  
demonstrating the feasibility to develop vaccines against any infectious  
disease. This review focuses on some recent advances in the  
identification of vaccine candidates by mining the genomic sequences of  
pathogenic bacteria.

**DESCRIPTORS:**

...ORGANISMS: Neisseria meningitidis (Neisseriaceae

...DISEASES: infectious disease, prevention and control

CHEMICALS & BIOCHEMICALS: ... vaccine ;

**MISCELLANEOUS TERMS:** ...Literature Review

17/K/3 (Item 3 from file: 5)

DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

...ABSTRACT: of cases: S. pneumoniae, N. meningitidis and H. influenzae  
type B. Routine administration of HIB vaccine in developed countries  
has resulted in a remarkable decline of meningitis with this bacterium.  
As...

...antibiotic coverage. Therapy aims at not only the sterilization of the  
CSF but also the prevention of inflammation as soon as possible. The  
physician should use antibiotics with bactericidal activity which...

**DESCRIPTORS:**

...ORGANISMS: Neisseria meningitis (Neisseriaceae

**MISCELLANEOUS TERMS:** ...Literature Review

17/K/4 (Item 4 from file: 5)

DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

**ABSTRACT:** Vaccines play a major role in the prevention of human birth  
defects by protecting the pregnant woman from teratogenic or otherwise  
harmful infections...

Untitled

...assumptions, many vaccines are now given to potentially pregnant women. Any new components of the vaccine formulation (adjuvants, excipients, stabilisers, preservatives, etc...) could also be tested for influences on development, although...

...may be employed as an aid for hazard identification. In these studies interactions of the vaccine with the maternal immune system or with the developmental systems of the offspring are considered...

...the immune system. Species selection for the preclinical studies is based on immunogenicity to the vaccine and the relative timing and rate of transfer of maternal antibodies to the offspring. A...

**DESCRIPTORS:**

ORGANISMS: *Neisseria meningitidis* (Neisseriaceae...)

CHEMICALS & BIOCHEMICALS: ... vaccine formulation components...

...polysaccharide group B meningococcal vaccine --

MISCELLANEOUS TERMS: ...Literature Review

17/K/5 (Item 5 from file: 5)

DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

A critical review of control strategies against meningococcal meningitis epidemics in sub-Saharan African countries

...ABSTRACT: evaluation of the emergency vaccination criteria. Despite current controversy on the immunogenicity of the polysaccharide vaccine , its safety, effectiveness in the field and low cost could justify the reopening of a...

...preventive - vaccination could significantly reduce the incidence of meningococcal meningitis and its severity. The conjugate vaccine , when available, will constitute an additional advantage in the prevention of meningococcal meningitis. A strategy combining both polysaccharide and conjugate vaccines according to the population...

**DESCRIPTORS:**

...ORGANISMS: *Neisseria meningitidis* (Neisseriaceae

CHEMICALS & BIOCHEMICALS: polysaccharide vaccine --...

...immunologic-drug, immunostimulant-drug, vaccine

MISCELLANEOUS TERMS: ...Literature Review

17/K/6 (Item 6 from file: 5)

DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

...ABSTRACT: most parts of the world with significant morbidity and mortality. Among the different serogroups of *Neisseria meningitidis*, serogroups A, B, C account for 90% of the disease. In the last few...

...of America and Sweden, and W135 in the Kingdom of Saudi Arabia. The emergence of *Neisseria meningitidis* serogroup W135 in the Kingdom of Saudi Arabia has lead to 2 major outbreaks...

Untitled

...This has lead the health officials in the Kingdom of Saudi Arabia to change their vaccine requirements for the Umra and Hajj to include the quadrivalent meningococcal vaccine (A, C, Y, W135) instead of the bivalent one (A, C). Despite all the advances in prevention , diagnosis and treatment, the disease continues to have high mortality (5-10%). Prompt empirical treatment for suspected cases should include penicillin or a 3rd generation cephalosporin. A new conjugate vaccine against *Neisseria meningitidis* serogroup C has been recently licensed, while quadrivalent conjugate vaccine against serogroup A, C, Y and W135 is in early development. Meanwhile targeted vaccination with...

**DESCRIPTORS:**

...ORGANISMS: *Neisseria meningitidis* (Neisseriaceae)

...DISEASES: bacterial disease, infectious disease, drug therapy, epidemiology, mortality, prevention and control

CHEMICALS & BIOCHEMICALS: ...quadrivalent meningococcal vaccine -....

... vaccine

MISCELLANEOUS TERMS: ...Literature Review

17/K/7 (Item 7 from file: 5)

DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

**DESCRIPTORS:**

...ORGANISMS: *Neisseria meningitidis* (Neisseriaceae)

CHEMICALS & BIOCHEMICALS: ...menigococci serogroup C vaccine -....

... vaccine ;

...METHODS & EQUIPMENT: immunization method, prevention method, protective method

MISCELLANEOUS TERMS: ...Literature Review

17/K/8 (Item 8 from file: 5)

DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

Molecular mimetics of polysaccharide epitopes as vaccine candidates for prevention of *Neisseria meningitidis* serogroup B disease

**ABSTRACT:** *Neisseria meningitidis* is a major cause of meningitis and sepsis. Despite nearly 25 years of work, there is no promising vaccine candidate for prevention of disease caused by meningococcal B strains. This review summarizes newer approaches for eliciting protective meningococcal B immune responses, including the use of molecular...

**DESCRIPTORS:**

...ORGANISMS: *Neisseria meningitidis* (Neisseriaceae)

DISEASES: *Neisseria meningitidis* serogroup B disease...

CHEMICALS & BIOCHEMICALS: ...immunostimulant-drug, vaccine ;

MISCELLANEOUS TERMS: ...Literature Review

17/K/9 (Item 9 from file: 5)

DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

...ABSTRACT: and the rate of antimicrobial resistance rises. Bacteria such

Untitled

as *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Neisseria meningitidis* are surrounded by polysaccharide capsules, as is the pathogenic yeast, *Cryptococcus neoformans*. The capsules of these organisms are central virulence factors for pathogenesis. Polysaccharide vaccines are available to prevent infection with the aforementioned bacterial pathogens, and an investigational vaccine has been developed for the prevention of cryptococcal disease. However, there are patient populations that remain at particularly high risk for...

...of antibody immunity in human *C. neoformans* infection has been more controversial. This article will review work from our laboratory on the human antibody response to the encapsulated organisms *C. neoformans*...

**DESCRIPTORS:**

...ORGANISMS: *Neisseria meningitidis* (Neisseriaceae)

MISCELLANEOUS TERMS: ...Literature Review

17/K/10 (Item 10 from file: 5)

DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

...ABSTRACT: and shown that it is related more closely to *Acinetobacter* spp. than to the genus *Neisseria* in which it was placed formerly. However, confusion with phenotypically similar *Neisseria* spp. can occur in the routine diagnostic laboratory if appropriate identification tests are not performed...

...organism's pathogenic properties and the host response to it may help to identify suitable vaccine targets or lead to other strategies to prevent infection. Whilst it remains, at present, the third most important respiratory pathogen, the impact of...

**DESCRIPTORS:**

...ORGANISMS: *Neisseria* (Neisseriaceae)

MISCELLANEOUS TERMS: ...Literature Review

? T S17/K/11-30

>>>KWIC option is not available in file(s): 399

17/K/11 (Item 11 from file: 5)

DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

Meningococcal disease prevention and control strategies for practice-based physicians

...ABSTRACT: adolescents. The increasing number of outbreaks since 1991 has raised questions about the management and prevention of further cases during an outbreak. The purpose of this statement is to guide primary-care physicians in their role in infection control and prevention of both sporadic cases and outbreaks of invasive meningococcal disease. This statement provides information on...

...for: (1) risk assessment of contacts, (2) administration of chemoprophylaxis, (3) appropriate use of meningococcal vaccine , (4) appropriate use of the microbiology laboratory, (5) the necessity for timely and appropriate reporting...

**DESCRIPTORS:**

...ORGANISMS: *Neisseria meningitidis* (Neisseriaceae)

Untitled

MISCELLANEOUS TERMS: ...Literature Review

17/K/12 (Item 12 from file: 5)  
DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

Mortality from group C meningococcal disease: A case for a conjugate vaccine ?

ABSTRACT: This 17-year retrospective review of children with meningococcal disease (MCD) has determined the mortality due to serogroup C, in order to assess the potential impact of a group C conjugate vaccine . Four hundred and forty-nine cases of MCD were admitted to our hospitals during 1977...

...total number of cases of MCD (151 vs 298). The currently available group C polysaccharide vaccine has low efficacy below 2 years of age and could not have prevented 54 cases of group C disease. A conjugate group C vaccine administered between 2 and 4 months of age could have prevented 68 cases, including all...

...is partly due to an increase in group C disease. A meningococcal group C conjugate vaccine could prevent most cases of infection due to group C, and decrease the mortality from MCD by...

DESCRIPTORS:

...ORGANISMS: Neisseria meningitidis (Neisseriaceae)

MISCELLANEOUS TERMS: ...POLYSACCHARIDE VACCINE ;

17/K/13 (Item 13 from file: 5)  
DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

Advances in biology, management and prevention of infections caused by Chlamydia trachomatis and Neisseria gonorrhoeae

DESCRIPTORS:

...ORGANISMS: Neisseria gonorrhoeae (Neisseriaceae)

MISCELLANEOUS TERMS: ... VACCINE ; ...

...Literature Review

17/K/14 (Item 14 from file: 5)  
DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

Prevention of childhood infection and its morbidity

...ABSTRACT: pertussis, tetanus, and polio. Concerns about the risk for adverse reactions to whole-cell pertussis vaccine are assuaged by risk-benefit studies; however, the development of a new acellular vaccine may offer a slightly less immunogenic but acceptable alternative for specific infants. Prevention of other serious infections is becoming a potential reality with development of effective vaccines against...

DESCRIPTORS:

...ORGANISMS: Neisseria meningitidis (Neisseriaceae)

Untitled

MISCELLANEOUS TERMS: ...DIPHTHERIA-TETANUS-PERTUSSIS VACCINE ; ...

...HEMOPHILUS VACCINE ; ...

...INFLUENZA VIRUS VACCINE ; ...

...MENINGOCOCCUS VACCINE ; ...

...POLIO VACCINE ; ...

...Literature Review

17/K/15 (Item 15 from file: 5)

DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

ABSTRACT: A retrospective review of 71 paediatric patients admitted with bacterial meningitis to the King Fahad Hospital at Al...

...streptococcus, which were responsible for 47.3, 34.5 and 9.1% of cases respectively. Neisseria meningitidis which is a major cause of meningitis in most other reports was uncommon in...

...were resistant to both ampicillin and chloramphenicol. There is a need for greater emphasis on prevention through the use of available vaccines including the newly introduced conjugate vaccines against HIB which...

DESCRIPTORS: HAEMOPHILUS-INFLUENZAE STREPTOCOCCUS-PNEUMONIAE NEISSERIA-MENINGITIDIS HUMAN AMPICILLIN CHLORAMPHENICOL ANTIBACTERIAL-DRUG CEREBROSPINAL FLUID VACCINE IMMUNE RESPONSE

17/K/16 (Item 16 from file: 5)

DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

#### VACCINE DEVELOPMENT FOR SEXUALLY TRANSMITTED DISEASES

ABSTRACT: Primary prevention of sexually transmitted diseases through immunization has been advocated as the most effective control strategy.

We review present efforts and future paths for development of gonococcal, chlamydial, treponemal, and genital herpes vaccines...

...the role of core groups, herd immunity, and mucosal surface immunity are examined. Hepatitis B vaccine is the possible success story of sexually transmitted disease vaccine development. A rational, well-researched implementation strategy that could serve as a model for other...

DESCRIPTORS: REVIEW NEISSERIA -GONORRHOEAE CHLAMYDIA-TRACHOMATIS TREPONEMA-PALLIDUM HERPES SIMPLEX VIRUS HEPATITIS B VIRUS MUCOSAL SURFACE IMMUNITY

17/K/17 (Item 1 from file: 34)

DIALOG(R)File 34:(c) 2008 The Thomson Corp. All rts. reserv.

...Abstract: the regulation of genes that are essential to their survival

Untitled

in the different environments. This review describes the current knowledge of gene expression by *B. burgdorferi* in the tick and the...

...better control of this prevalent infection and the design of new, second generation vaccines to prevent infection with the spirochete. (C)

2003 Federation of European Microbiological Societies. Published by Elsevier B...

...Identifiers--LYME-DISEASE SPIROCHETE; CENTRAL-NERVOUS-SYSTEM; MHC CLASS-II; FACTOR-H; IN-VIVO; PROTECTIVE ANTIBODIES; NEISSERIA -GONORRHOEAE; TREATMENT-RESISTANT; SERUM RESISTANCE

17/K/18 (Item 2 from file: 34)

DIALOG(R)File 34:(c) 2008 The Thomson Corp. All rts. reserv.

Title: Prevention of life-threatening infections due to encapsulated bacteria in children with hyposplenia or asplenia: a brief review of current recommendations for practical purposes

...Abstract: of the present work was to summarise in a single paper all the options for prevention of life-threatening infections due to encapsulated bacteria in patients with hyposplenism or asplenia. Prevention of these infections should be obtained in all patients with 1) patient and family education...

...salvage in splenic trauma. Vaccination is not effective against all serotypes of *S. pneumoniae* and *Neisseria meningitidis* causing life-threatening infections in hypo/asplenic patients. Moreover, antibacterial prophylaxis could select antibacterial...

...Identifiers--PNEUMOCOCCAL POLYSACCHARIDE VACCINE ; INFLUENZAE TYPE-B; POSTSPLENECTOMY INFECTION; STREPTOCOCCUS-PNEUMONIAE; HEREDITARY SPHEROCYTOSIS; ANTIBIOTIC-PROPHYLAXIS; CELL TRANSPLANTATION; OVERWHELMING SEPSIS; CONJUGATE VACCINE ; SPLENECTOMY

17/K/19 (Item 3 from file: 34)

DIALOG(R)File 34:(c) 2008 The Thomson Corp. All rts. reserv.

Abstract: This review comprises aspects of the epidemiology, microbiology, pathophysiology, clinical manifestations, diagnosis, management, prognosis, and prevention of bacterial meningitis, with emphasis on the paediatric population. The beginning of this millennium has...

...outcome from disease. Novel strategies are needed to distribute and implement effective vaccines worldwide to prevent bacterial meningitis.

...Identifiers--PERMEABILITY-INCREASING PROTEIN; EXPERIMENTAL PNEUMOCOCCAL MENINGITIS; RESISTANT STREPTOCOCCUS-PNEUMONIAE; SEVERE MENINGOCOCCAL SEPSIS; CEREBROSPINAL-FLUID VALUES; NEISSERIA -MENINGITIDIS; DEXAMETHASONE THERAPY; CONJUGATE VACCINE ; UNITED-STATES

17/K/20 (Item 4 from file: 34)

DIALOG(R)File 34:(c) 2008 The Thomson Corp. All rts. reserv.

Untitled

Title: Recent developments in vaccines to prevent meningococcal serogroup B infections

...Abstract: B. Despite the availability of successful meningococcal serogroup C conjugate vaccines, there is no effective vaccine against serogroup B. Efficacy trials with outer membrane vesicle (OMV) vaccines were ineffective and are...

...therefore being investigated. The completion of the meningococcal genome sequence has provided new challenges. This review summarizes recent developments in the search for a broadly protective meningococcal serogroup B vaccine.

...Identifiers--MEMBRANE VESICLE VACCINE ; NEISSERIA -MENINGITIDIS STRAINS; OUTER-MEMBRANE; SERUM ANTIBODIES; INNER-CORE; MONOCLONAL-ANTIBODIES; BACTERICIDAL ACTIVITY; CROSS-REACT; PROTEIN...

17/K/21 (Item 5 from file: 34)

DIALOG(R)File 34:(c) 2008 The Thomson Corp. All rts. reserv.

Title: Meningococcal disease: how to prevent and how to manage

...Abstract: improved the success of vaccination in reducing the incidence of meningococcal disease. However, a comprehensive vaccine conferring protection against disease-associated serogroups remains elusive. The aim of this review is to highlight recent significant improvements in the prevention and management of meningococcal disease.

...Identifiers--MENINGITIDIS SEROGROUP-B; OUTER-MEMBRANE PROTEIN; C CONJUGATE VACCINE ; NEISSERIA -MENINGITIDIS; VESICLE VACCINE ; SEPTIC SHOCK; CAPSULAR POLYSACCHARIDE; BACTERICIDAL ACTIVITY; EMERGENCY MANAGEMENT; IMMUNOLOGICAL MEMORY

17/K/22 (Item 6 from file: 34)

DIALOG(R)File 34:(c) 2008 The Thomson Corp. All rts. reserv.

Title: A critical review of control strategies with regard to meningococcal meningitis epidemics in Sub-Saharan African countries.

...Abstract: event of declared epidemic. However the obvious failure of this strategy has meant that a review and evaluation of the emergency vaccination criteria is necessary. In spite of the current controversy regarding the immunogenicity of the polysaccharide vaccine , its safety, effectiveness in the field and low cost should justify the renewal of a...

...could significantly reduce the incidence of meningococcal meningitis as well as its severity. The conjugate vaccine , when available, will constitute an additional advantage in the prevention of meningococcal meningitis, The organisation of a strategy combining both polysaccharide and conjugate vaccines according...

...Identifiers--CAPSULAR POLYSACCHARIDE VACCINE ; NEISSERIA -MENINGITIDIS; WEST-AFRICA; BACTERIAL-MENINGITIS; ANTIBODY-RESPONSE; SEROGROUP-C; IMMUNIZATION; CARRIAGE; DISEASE; CHILDREN

17/K/23 (Item 7 from file: 34)

DIALOG(R)File 34:(c) 2008 The Thomson Corp. All rts. reserv.

## Untitled

**Abstract:** Development of the meningococcal serogroup C conjugate vaccine and its national implementation in the UK has been a major breakthrough in the prevention of meningococcal disease. New technologies are increasing the likelihood that research towards a vaccine against group B meningococcus will be successful. This review covers the recent development of vaccines against meningococcal disease and examines future vaccine candidates. The development of meningococcal polysaccharide vaccines was based on the virulence of the bacterial...

...LPS). New genome sequencing technology promises a way forward to developing a broadly cross-protective vaccine for this important pathogen.

...Identifiers--RANDOMIZED CONTROLLED TRIAL; MEMBRANE-VESICLE VACCINE ; PROTEIN CONJUGATE VACCINE ; B NEISSERIA -MENINGITIDIS; CAPSULAR POLYSACCHARIDE VACCINE ; LINKED-IMMUNOSORBENT-ASSAY; C-POLYSACCHARIDE; GROUP-A; IMMUNOLOGICAL MEMORY; IMMUNE-RESPONSES

17/K/24 (Item 8 from file: 34)  
DIALOG(R)File 34:(c) 2008 The Thomson Corp. All rts. reserv.

...Abstract: which commensal and pathogenic bacteria are restricted to certain hosts, tissue and cell types. This review was done to shed light on the initiating factors in bacterial disease, more particularly those...

...of urinary tract infection. Understanding the molecular events responsible may lead to development of a vaccine to prevent urinary tract infection.

...Identifiers--GENE-TRANSFER; INFLUENZAE TYPE-B; EPITHELIAL-CELLS; VIRULENCE FACTORS; P-FIMBRIAE; HUMAN-ERYTHROCYTES; IMMOBILIZED FIBRONECTIN; NEISSERIA -MENINGITIDIS; HEMOPHILUS-INFLUENZAE

17/K/25 (Item 1 from file: 45)  
DIALOG(R)File 45:(c) 2008 Elsevier B.V. All rts. reserv.

Prevention and management of overwhelming postsplenectomy infection - An update

Objectives: To review the diagnosis and management of overwhelming postsplenectomy infection and to discuss various preventative measures.

Data...

DESCRIPTORS:

\*Pneumococcus vaccine ; \*splenectomy; \*infection; \*sepsis; \*asplenia; \* prevention

...guideline; medical literature; clinical feature; disease course; influenza vaccination; Haemophilus influenzae type b; serology; human; Neisseria meningitidis; patient education; priority journal; septic shock; risk factor; MEDLINE; algorithm; diagnosis; data extraction; etiology...

17/K/26 (Item 2 from file: 45)  
DIALOG(R)File 45:(c) 2008 Elsevier B.V. All rts. reserv.

## Untitled

...Africa, where serogroup A meningococcal disease is periodically a problem of massive epidemic proportions. This review focuses on developments in our understanding of the diagnosis and treatment of meningococcal disease, of...

...to, and severity of, this infection, and on advances which may eventually lead to its prevention .

**DESCRIPTORS:**

Meningococcus vaccine ; Neisseria meningitidis; disease severity; prevention ; disease predisposition; clinical feature; bacterial mutation; disease transmission; host resistance; priority journal; vaccine production; strain difference; human; Haemophilus influenzae type b; pathogenesis; meningitis; epidemic; diagnosis; infection; Africa

17/K/27 (Item 3 from file: 45)

DIALOG(R)File 45:(c) 2008 Elsevier B.V. All rts. reserv.

...great health problem on all continents and the meningococcal vaccines have been proposed for their prevention and epidemic control. The polysaccharide A and C vaccines are relatively efficacious with distinct immunological...

...with regard to the different age groups, however, up to the present no highly efficacious vaccine for meningococcal B disease exists. The meningococcal B capsular polysaccharide is not immunogenic due to...

...and efforts to produce carrier proteins have been proposed in order to obtain an immunogenic vaccine for all age groups that would if possible, protect against all the meningococci. This review of the literature presents the study of the development of the immunological behavior of all

...

**DESCRIPTORS:**

\*Meningococcus vaccine ; \*bacterial vaccine ; \*meningitis; \*immunity; \* immunology  
vaccine ; polysaccharide; carrier protein; groups by age; meningococcosis; Neisseria meningitidis; drug safety; drug efficacy; vaccination; human; health; tissue; mammal; epidemic; prevention

17/K/28 (Item 4 from file: 45)

DIALOG(R)File 45:(c) 2008 Elsevier B.V. All rts. reserv.

In this article we review the epidemiological features of Haemophilus influenzae type b (Hib) in Spain and we compare them with those of other countries. We also review , the different studies and clinical trials carried out with different vaccines versus Hib in order...

...order of frequency after meningococcus and it is estimated to cause 20% of the total. Prevention is the best way of fighting this disease and for this purpose we now have...

**DESCRIPTORS:**

\*Haemophilus influenzae type b vaccine ; \*Haemophilus influenzae type b; \* meningitis; \*active immunization; \*infection; \*epidemiology

Untitled

vaccine ; diphtheria pertussis tetanus vaccine ; poliomyelitis vaccine ; Spain; immunogenicity; diarrhea; drug efficacy; drug safety; erythema; fever; inflammation; host resistance; vomiting; human; intramuscular drug administration; prevention ; bacterial infection; pharmacist; immunization ; fighting; risk; hospital patient; child; bacterial meningitis; Neisseria meningitidis; clinical trial; safety

17/K/29 (Item 1 from file: 71)  
DIALOG(R)File 71:(c) 2008 Elsevier B.V. All rts. reserv.

...capsular polysaccharide of Haemophilus influenzae type b, common serotypes of Streptococcus pneumoniae and group C Neisseria meningitidis are covalently bound to a protein antigen to convert a T-cell-independent immune response into a T-cell-dependent response have proved highly effective in the prevention of invasive disease in infants and young children. This review looks at what has been learnt from developing these vaccines that could be useful for...

...vaccines, in such areas as combination vaccines, dose-ranging, cross-protection of closely related antigens, prevention of noninvasive disease, correlates of protection and use in older age groups. In addition, a...

**DESCRIPTORS:**

Candida albicans; Capsular polysaccharide; Cholera; Combination vaccines; Conjugate vaccine ; Cryptococcus; E. coli; Haemophilus; Lipopolysaccharide ; Meningococcal; Pneumococcal; Shigella; Staphylococcus aureus; Typhoid

17/K/30 (Item 1 from file: 73)  
DIALOG(R)File 73:(c) 2008 Elsevier B.V. All rts. reserv.

...A/C polysaccharide. The high cost and short supply of quadrivalent (A,C,Y, W135) vaccine to protect against W135 disease has added to what was already the significant burden of...

**DRUG DESCRIPTORS:**

glycoconjugate--pharmacology--pd; Meningococcus vaccine --drug therapy--dt ; Meningococcus vaccine --pharmacoeconomics--pe; Meningococcus vaccine --pharmacology--pd; outer membrane protein; polysaccharide vaccine --drug therapy--dt; polysaccharide vaccine --pharmacoeconomics--pe; polysaccharide vaccine --pharmacology--pd

**MEDICAL DESCRIPTORS:**

\*meningococcosis--disease management--dm; \*meningococcosis--drug therapy --dt; \*meningococcosis--epidemiology--ep; \*meningococcosis--etiology--et; \*meningococcosis-- prevention --pc

...transmission; epidemic; genetic transformation; genetic variability; health survey; housekeeping gene; human; incidence; multilocus enzyme electrophoresis; Neisseria lactamica; Neisseria meningitidis; pathogenicity; priority journal; review ; seasonal variation; vaccination

? T S17/K/31-50

>>>KWIC option is not available in file(s): 399

17/K/31 (Item 2 from file: 73)  
DIALOG(R)File 73:(c) 2008 Elsevier B.V. All rts. reserv.

## Untitled

...as the classical diplococcal pneumonia, the gram-positive Streptococcus pneumoniae (the pneumococcus), infections due to Neisseria meningitidis (the meningococcus), and Moraxella catarrhalis (formerly called both Neisseria catarrhalis and Branhamella catarrhalis) are addressed here including their microbiology, respiratory tract manifestations, antimicrobial treatment and potential prevention with immunization.

Copyright (c) 2003 by Current Science Inc.

**DRUG DESCRIPTORS:**

...administration--po; clindamycin--drug therapy--dt; lipooligosaccharide --endogenous compound--ec; macrolide--drug therapy--dt; Meningococcus vaccine --drug therapy--dt; meticillin--drug therapy--dt; outer membrane protein--endogenous compound--ec; penicillin G...

**MEDICAL DESCRIPTORS:**

...\*di; \*Gram negative infection--drug therapy--dt; \*Gram negative infection--epidemiology--ep; \*Gram negative infection-- prevention --pc; \*respiratory tract infection--diagnosis--di; \*respiratory tract infection --drug therapy--dt; \*respiratory tract infection--epidemiology--ep; \*respiratory tract infection-- prevention --pc  
...bacterium pilus; clinical feature; drug dose regimen; drug sensitivity; fimbria; human; immunization; microbiology; Moraxella catarrhalis; Neisseria meningitidis; nonhuman; prevalence; review

17/K/32 (Item 3 from file: 73)

DIALOG(R)File 73:(c) 2008 Elsevier B.V. All rts. reserv.

...used for evaluating vaccination strategies. We shall confront the findings with observations, and we shall review some practical cases where modelling vaccination strategies has provided crucial insights into how vaccination affects...

**DRUG DESCRIPTORS:**

BCG vaccine --drug therapy--dt; chickenpox vaccine --drug therapy--dt; diphtheria pertussis tetanus vaccine --drug therapy--dt; Haemophilus influenzae type b vaccine --drug therapy--dt; hepatitis B vaccine --drug therapy--dt; measles vaccine --drug therapy--dt; meningitis vaccine --drug therapy--dt; Meningococcus vaccine --drug therapy--dt; mumps vaccine --drug therapy--dt; Pneumococcus vaccine --drug therapy--dt; poliomyelitis vaccine --drug therapy--dt; rubella vaccine --drug therapy --dt; smallpox vaccine --drug therapy--dt

**MEDICAL DESCRIPTORS:**

article; bacterial infection--drug therapy--dt; bacterial infection --etiology--et; bacterial infection-- prevention --pc; bacterial meningitis --drug therapy--dt; bacterial meningitis--etiology--et; bacterial meningitis-- prevention --pc; Bordetella pertussis; chickenpox--drug therapy--dt; chickenpox--etiology--et; chickenpox-- prevention --pc; clinical observation; Corynebacterium diphtheriae; Denmark; diphtheria --drug therapy--dt; diphtheria--etiology--et; diphtheria-- prevention --pc; disease transmission; epidemic; Finland; Haemophilus influenzae type b; health program; hepatitis B--drug therapy--dt; hepatitis B--etiology--et; hepatitis B-- prevention --pc; Hepatitis B virus; human; incidence; infection control; infection sensitivity; life history; mathematical analysis; mathematical model; measles--drug therapy--dt; measles--etiology --et; measles-- prevention --pc; Measles virus; meningococcosis--drug therapy--dt; meningococcosis--etiology--et; meningococcosis-- prevention

Untitled

--pc; microbial immunity; mumps--drug therapy--dt; mumps--etiology--et; mumps-- prevention --pc; Mumps virus; Neisseria meningitidis; Netherlands ; pertussis--drug therapy--dt; pertussis--etiology--et; pertussis-- prevention --pc; poliomyelitis--drug therapy--dt; poliomyelitis--etiology --et; poliomyelitis-- prevention --pc; Poliomyelitis virus; rubella--drug therapy--dt; rubella--etiology--et; rubella-- prevention --pc; Rubella virus; smallpox--drug therapy--dt; smallpox--etiology--et; smallpox-- prevention --pc; Smallpox virus; Streptococcus infection--drug therapy--dt; Streptococcus infection--etiology--et; Streptococcus infection-- prevention --pc; Streptococcus pneumoniae; tuberculosis--drug therapy--dt; tuberculosis--etiology--et; tuberculosis-- prevention --pc; Varicella zoster virus

CAS REGISTRY NO.: 126161-67-9 (Haemophilus influenzae type b vaccine )

17/K/33 (Item 4 from file: 73)

DIALOG(R)File 73:(c) 2008 Elsevier B.V. All rts. reserv.

**DRUG DESCRIPTORS:**

...do; ethambutol--drug therapy--dt; gentamicin--drug therapy--dt; glucocorticoid--drug therapy--dt; Haemophilus influenzae vaccine --drug therapy--dt; heparin--drug therapy--dt; isoniazid--adverse drug reaction --ac; isoniazid--drug dose...

**MEDICAL DESCRIPTORS:**

...\*bacterial meningitis--drug therapy--dt; \*bacterial meningitis --epidemiology--ep; \*bacterial meningitis--etiology--et; \*bacterial meningitis-- prevention --pc  
...fever; Haemophilus influenzae; headache; hearing loss--complication--co; hearing loss--drug therapy--dt; hearing loss-- prevention --pc; human; hydrocephalus--complication--co; hydrocephalus--etiology--et; hyperventilation; intracranial hypertension--complication--co; lumbar puncture; Lyme disease--diagnosis--di; Lyme disease--drug therapy--dt; Lyme disease--etiology--et; Neisseria meningitidis; neurologic disease --diagnosis--di; nuclear magnetic resonance imaging; outcomes research; pathogenesis; peripheral neuropathy--side effect--si; practice guideline; prognosis; review ; seizure--complication--co; seizure--drug therapy--dt; Staphylococcus; tuberculous meningitis--diagnosis--di; tuberculous meningitis--drug...

17/K/34 (Item 5 from file: 73)

DIALOG(R)File 73:(c) 2008 Elsevier B.V. All rts. reserv.

This article is intended to review the state of the art in the field of immunization. Streptococcus pneumoniae, Neisseria meningitidis, Bordetella pertussis, Hepatitis A, Hepatitis B, Varicella, Polio vaccine , Influenza and Rabies are discussed.

**MEDICAL DESCRIPTORS:**

...dt; poliomyelitis--etiology--et; poliomyelitis--prevention--pc; rabies --drug therapy--dt; rabies--etiology--et; rabies-- prevention --pc; review ; Streptococcus infection--drug therapy--dt; Streptococcus infection --etiology--et; Streptococcus infection-- prevention --pc; Streptococcus pneumonia--drug therapy--dt; Streptococcus pneumonia--etiology--et; Streptococcus pneumonia-- prevention --pc; Streptococcus pneumoniae; treatment indication

Untitled

17/K/35 (Item 6 from file: 73)  
DIALOG(R)File 73:(c) 2008 Elsevier B.V. All rts. reserv.

There is a major need for an effective vaccine against serogroup B disease. The long-term efficacy of the serogroups A, C, Y and...

DRUG DESCRIPTORS:

\*Meningococcus vaccine --clinical trial--ct; \*Meningococcus vaccine --drug comparison--cm; \*Meningococcus vaccine --drug therapy--dt; \* polysaccharide vaccine --clinical trial--ct; \*polysaccharide vaccine --drug comparison--cm; \*polysaccharide vaccine --drug therapy--dt

MEDICAL DESCRIPTORS:

\*epidemic meningitis--drug therapy--dt; \*epidemic meningitis--epidemiology --ep; \*epidemic meningitis--etiology--et; \*epidemic meningitis-- prevention --pc; \* Neisseria meningitidis

...drug response; human; immunogenicity; incidence; infection control; infection resistance; nonhuman; pathogenesis; prevalence; priority journal; revaccination; review ; vaccination

DRUG TERMS (UNCONTROLLED): monoclonal antibody b5; neisserial surface protein a; protein frpb; serogroup a meningococcal polysaccharide vaccine --drug comparison--cm; serogroup a meningococcal polysaccharide vaccine --drug therapy--dt; serogroup c meningococcal polysaccharide vaccine --clinical trial--ct; serogroup c meningococcal polysaccharide vaccine --drug therapy--dt

17/K/36 (Item 7 from file: 73)  
DIALOG(R)File 73:(c) 2008 Elsevier B.V. All rts. reserv.

Maternal immunization embraces the concepts that vaccines given to pregnant women enhance their resistance to vaccine -preventable diseases and passive antibodies that cross the placenta protect the neonate for the first...

DRUG DESCRIPTORS:

aciclovir--drug therapy--dt; beta lactam antibiotic--drug therapy--dt; chickenpox vaccine --drug therapy--dt; diphtheria tetanus toxoid--drug therapy--dt; erythromycin--drug therapy--dt; hepatitis A...

...hepatitis A antibody--drug therapy--dt; hepatitis A antibody --intramuscular drug administration--im; hepatitis A vaccine --adverse drug reaction--ae; hepatitis A vaccine --drug combination--cb; hepatitis A vaccine --drug therapy--dt; hepatitis A vaccine --intramuscular drug administration--im; hepatitis B antibody--drug combination--cb; hepatitis B antibody--drug therapy--dt; hepatitis B vaccine --drug combination--cb; hepatitis B vaccine --drug therapy--dt; hepatitis B vaccine --intramuscular drug administration--im; influenza vaccine --adverse drug reaction--ae; influenza vaccine --drug therapy--dt; measles antibody--drug therapy--dt; measles mumps rubella vaccine --drug toxicity--to; measles vaccine --drug toxicity--to; Meningococcus vaccine --drug therapy--dt; Meningococcus vaccine --subcutaneous drug administration--sc; oral poliomyelitis vaccine --drug therapy--dt; oral poliomyelitis vaccine --oral drug administration--po; penicillin G--drug therapy--dt; Pneumococcus vaccine --adverse drug reaction--ae; Pneumococcus vaccine --drug therapy--dt; Pneumococcus vaccine --intramuscular drug

Untitled

administration--im; poliomyelitis vaccine --drug therapy--dt; rabies immunoglobulin--drug therapy--dt; tetanus antibody--drug therapy--dt; unclassified drug; yellow fever vaccine --adverse drug reaction--ae; yellow fever vaccine --drug therapy--dt; yellow fever vaccine --drug toxicity--to

MEDICAL DESCRIPTORS:

...therapy--dt; botulism--etiology--et; breast feeding; chickenpox--drug therapy--dt; chickenpox--etiology--et; chickenpox-- prevention --pc; congenital malformation--congenital disorder--cn; diphtheria--drug therapy --dt; diphtheria-- prevention --pc; drug contraindication; drug indication; drug safety; epidemic; fetotoxicity; hepatitis A--drug therapy--dt; hepatitis A--epidemiology--ep; hepatitis A--etiology--et; hepatitis A-- prevention --pc; Hepatitis A virus; hepatitis B--diagnosis--di; hepatitis B --drug therapy--dt; hepatitis B--etiology--et; hepatitis B-- prevention --pc; high risk population; human; infection prevention ; infection risk; influenza--drug therapy--dt; influenza--epidemiology--ep; influenza --etiology--et; influenza-- prevention --pc; influenza vaccination; intrauterine growth retardation--complication--co; measles--drug therapy --dt; measles--etiology--et; measles-- prevention --pc; measles vaccination ; meningococcemia--drug therapy--dt; meningococcemia--epidemiology--ep; meningococcemia--etiology--et; meningococcemia-- prevention --pc; Neisseria meningitidis; penicillin resistance; poliomyelitis--drug therapy --dt; poliomyelitis--etiology--et; poliomyelitis-- prevention --pc; pregnancy; prenatal screening; priority journal; review ; risk benefit analysis; side effect--side effect--si; spontaneous abortion--side effect --si; Streptococcus infection...

...Streptococcus infection--drug therapy--dt; Streptococcus infection --epidemiology--ep; Streptococcus infection--etiology--et; Streptococcus infection-- prevention --pc; Streptococcus pneumoniae; teratogenicity; tetanus--drug therapy--dt; tetanus-- prevention --pc; treatment indication; Varicella zoster virus; virus transmission; yellow fever--drug therapy--dt; yellow fever...

17/K/37 (Item 8 from file: 73)

DIALOG(R)File 73:(c) 2008 Elsevier B.V. All rts. reserv.

DRUG DESCRIPTORS:

\*bacterial antigen--pharmacology--pd; \*bacterial polysaccharide --pharmacology--pd; \*bacterial vaccine --pharmacology--pd  
DNA vaccine ; Haemophilus influenzae type b vaccine --drug therapy--dt; Haemophilus influenzae type b vaccine --pharmacology--pd; immunoglobulin G --endogenous compound--ec; immunoglobulin G antibody--endogenous compound --ec; Meningococcus vaccine --drug therapy--dt; Meningococcus vaccine --pharmacology--pd; Streptococcus vaccine ; T lymphocyte antigen; virulence factor

MEDICAL DESCRIPTORS:

...\*bacterial meningitis--drug therapy--dt; \*bacterial meningitis --epidemiology--ep; \*bacterial meningitis--etiology--et; \*bacterial meningitis-- prevention --pc; \*influenza--drug therapy--dt; \*influenza --etiology--et; \*influenza-- prevention --pc; \*otitis media--epidemiology --ep; \*otitis media--etiology--et; \*Streptococcus pneumonia--drug therapy --dt; \*Streptococcus pneumonia--epidemiology--ep; \*Streptococcus pneumonia --etiology--et; \*Streptococcus pneumonia-- prevention --pc

Untitled

...immunization; immunogenicity; immunology; lower respiratory tract infection--epidemiology--ep; lower respiratory tract infection--etiology--et; Neisseria meningitidis; nonhuman; phage display; priority journal; review ; Streptococcus agalactiae; Streptococcus pneumoniae; T lymphocyte  
CAS REGISTRY NO.: 126161-67-9 (Haemophilus influenzae type b vaccine );  
97794-27-9 (immunoglobulin G)

17/K/38 (Item 9 from file: 73)  
DIALOG(R)File 73:(c) 2008 Elsevier B.V. All rts. reserv.

Epidemiology and therapy of infections caused by *Neisseria meningitidis*  
Epidemiologia i leczenie zakazen wywolanych przez *Neisseria meningitidis*

In spite of the progress in antibiotic therapy and immunoprophylaxis *Neisseria meningitidis* remains one of the major causes of meningitis and sepsis burdened by high mortality...

**DRUG DESCRIPTORS:**

cephalosporin derivative--drug therapy--dt; chloramphenicol--drug therapy--dt; meningitis vaccine --drug therapy--dt; Meningococcus vaccine ; penicillin derivative--drug therapy--dt; unclassified drug

**MEDICAL DESCRIPTORS:**

...\*bacterial meningitis--drug therapy--dt; \*bacterial meningitis --epidemiology--ep; \*bacterial meningitis--etiology--et; \*bacterial meningitis-- prevention --pc; \* *Neisseria meningitidis* antibiotic resistance; antibiotic therapy; bacterial virulence; chemoprophylaxis; clinical feature; human; infection prevention ; mortality; Poland; prevalence; review

17/K/39 (Item 10 from file: 73)  
DIALOG(R)File 73:(c) 2008 Elsevier B.V. All rts. reserv.

...in the laboratory. Scientists are investigating which of these, used intravaginally by women, will safely prevent the sexual transmission of HIV in humans. Several such products - microbicides - will soon be tested

...

**DRUG DESCRIPTORS:**

...virus antibody--drug development--dv; Human immunodeficiency virus antibody--drug therapy--dt; Human immunodeficiency virus vaccine --drug development--dv; Human immunodeficiency virus vaccine --drug therapy--dt; hydrogen peroxide--drug development--dv; hydrogen peroxide--drug therapy--dt; magainin derivative...

**MEDICAL DESCRIPTORS:**

...\*virus infection--drug therapy--dt; \*Human immunodeficiency virus infection--etiology--et; \*Human immunodeficiency virus infection-- prevention --pc; \*sexually transmitted disease--drug resistance--dr; \* sexually transmitted disease--drug therapy--dt; \*sexually transmitted disease--etiology--et; \*sexually transmitted disease-- prevention --pc antibiotic resistance; Chlamydia trachomatis; chlamydiasis--drug therapy --dt; chlamydiasis--etiology--et; chlamydiasis-- prevention --pc; condom; drug efficacy; drug research; drug safety; female; genital ulcer--side effect--si; gonorrhea--drug therapy--dt; gonorrhea--etiology--et; gonorrhea -- prevention --pc; high risk population; human; Human immunodeficiency

Untitled  
virus; Neisseria gonorrhoeae; pregnancy; priority journal; prophylaxis;  
public health service; review ; sexual behavior; sexual transmission;  
treatment outcome

17/K/40 (Item 11 from file: 73)  
DIALOG(R)File 73:(c) 2008 Elsevier B.V. All rts. reserv.

Meningococcal serogroup B infections: A search for a broadly protective vaccine

...is mainly caused by serogroup B in many West European countries.  
Recently, a highly efficacious vaccine against infections caused by serogroup C has been introduced in the UK and The Netherlands. However, an effective vaccine against serogroup B has not yet become available. Outer membrane vesicle vaccines against serogroup B...

...of the meningococcal genome has provided new opportunities to detect additional immunogenic epitopes. In this review , the developments in the search for a broadly protective meningococcal serogroup B vaccine will be discussed.

DRUG DESCRIPTORS:

\*Meningococcus vaccine --clinical trial--ct; \*Meningococcus vaccine --drug development--dv; \*Meningococcus vaccine --drug therapy--dt antigen; bacterial antigen; bacterium lipopolysaccharide--drug development --dv; bacterium lipopolysaccharide--pharmacology--pd; epitope; Haemophilus influenzae vaccine --drug development--dv; outer membrane protein; porin; unclassified drug

MEDICAL DESCRIPTORS:

\*meningococciosis--drug therapy--dt; \*meningococciosis-- prevention --pc ...bacterial strain; clinical trial; drug efficacy; gene control; gene expression; gene sequence; genomics; human; immunogenicity; Neisseria meningitidis; priority journal; review

DRUG TERMS (UNCONTROLLED): app vaccine --drug development--dv; autotransported serine protease a vaccine --drug development--dv; capsular polysaccharide vaccine --drug development--dv; genome derived neisseria antigen 1870 vaccine --drug development--dv; genome derived neisseria antigen 1870 vaccine --pharmacology--pd; genome derived neisseria antigen 2132 vaccine --drug development--dv; genome derived neisseria antigen 2132 vaccine --pharmacology--pd; genome derived neisseria antigen 33 vaccine --drug development--dv; genome derived neisseria antigen 33 vaccine --pharmacology--pd; nada vaccine --drug development --dv; nada vaccine --pharmacology--pd; neisseria meningitidis surface protein a vaccine --drug development--dv; neisseria meningitidis surface protein a vaccine --pharmacology--pd; outer membrane vesicle vaccine --drug development--dv; outer membrane vesicle vaccine --intramuscular drug administration--im; outer membrane vesicle vaccine --intranasal drug administration--na; outer membrane vesicle vaccine --pharmacology--pd; p2086--drug development--dv; porin A; recombinant porin vaccine --drug development--dv; transferrin binding protein a vaccine --drug combination --cb; transferrin binding protein a vaccine --drug development--dv; transferrin binding protein a vaccine --pharmacology--pd; transferrin binding protein b vaccine --drug combination--cb; transferrin binding protein b vaccine --drug development--dv; transferrin binding protein b vaccine --pharmacology--pd

## Untitled

17/K/41 (Item 12 from file: 73)  
DIALOG(R)File 73:(c) 2008 Elsevier B.V. All rts. reserv.

...was identified and a mass vaccination campaign was carried out, using the newly licensed conjugate vaccine . Clinical, epidemiological, economic and social studies were instrumental in the decision making for implementing these...

**DRUG DESCRIPTORS:**

Meningococcus vaccine --drug therapy--dt; polysaccharide vaccine --drug therapy--dt

**MEDICAL DESCRIPTORS:**

\*meningococcosis--drug therapy--dt; \*meningococcosis--etiology--et; \* meningococcosis-- prevention --pc

Canada; decision making; disease control; economic aspect; health program; human; immunization; infection control; Neisseria meningitidis; prophylaxis; public health; review ; social aspect; vaccination

17/K/42 (Item 13 from file: 73)  
DIALOG(R)File 73:(c) 2008 Elsevier B.V. All rts. reserv.

**Neisseria meningitidis serogroup A vaccines: An overview**

A recent report by the Weekly Epidemiological Record of an outbreak of Neisseria meningitidis serogroup A in the Great Lakes region shows that meningococcal epidemics are an unsolved...

...1990s, about 350,000 people developed meningitis and 1000 people died [101]. An effective polysaccharide vaccine has been available since the early 1970s. Unfortunately, attempts to contain the epidemics by timely detection of cases through active surveillance and prompt mass vaccination campaigns have failed to prevent the deaths of thousands of people in several African countries in the 1980s and 1990s...

...policies and their economic implications are discussed, to clarify why the use of an effective vaccine has, to date, been disappointing. The recent exciting developments with respect to conjugate vaccines are...

**DRUG DESCRIPTORS:**

\*Meningococcus vaccine --adverse drug reaction--ae; \*Meningococcus vaccine --clinical trial--ct; \*Meningococcus vaccine --drug development --dv; \*Meningococcus vaccine --drug dose--do; \*Meningococcus vaccine --drug therapy--dt; \*Meningococcus vaccine --pharmaceutics--pr; \* Meningococcus vaccine --pharmacology--pd; \*polysaccharide vaccine --adverse drug reaction--ae; \*polysaccharide vaccine --clinical trial--ct; \*polysaccharide vaccine --drug development--dv; \*polysaccharide vaccine --drug dose--do; \*polysaccharide vaccine --drug therapy--dt; \* polysaccharide vaccine --pharmaceutics--pr; \*polysaccharide vaccine --pharmacology--pd  
diphtheria toxin--drug dose--do; diphtheria toxoid--drug dose--do; inactivated vaccine ; poliomyelitis vaccine ; unclassified drug

**MEDICAL DESCRIPTORS:**

\*epidemic meningitis--drug therapy--dt; \*epidemic meningitis--epidemiology --ep; \*epidemic meningitis--etiology--et; \*epidemic meningitis-- prevention

Untitled

--pc; \* *Neisseria meningitidis*  
...effect--si; drug formulation; epidemic; epidemiological data; geographic distribution; human; immunogenicity; infection control; priority journal; review ; treatment outcome; vaccination; vaccination reaction--side effect  
--si

DRUG TERMS (UNCONTROLLED): acw 135; meningococcus a conjugate vaccine  
--adverse drug reaction--ae; meningococcus a conjugate vaccine --drug development--dv; meningococcus a conjugate vaccine --drug therapy--dt; meningococcus a conjugate vaccine --pharmaceutics--pr; meningococcus a conjugate vaccine --pharmacology--pd; meningococcus c conjugate vaccine --drug development--dv; meningococcus c conjugate vaccine --drug therapy--dt; meningococcus c conjugate vaccine --pharmaceutics--pr; meningococcus c conjugate vaccine --pharmacology--pd; w 135

17/K/43 (Item 14 from file: 73)  
DIALOG(R)File 73:(c) 2008 Elsevier B.V. All rts. reserv.

...problem of bacterial meningitis will only be solved if protein-conjugate vaccines (or other effective vaccine strategies) against *S. pneumonia*, *H. influenzae* and epidemic strains of *Neisseria meningitidis* are available to all the world's children. Making third-generation cephalosporins affordable in...

DRUG DESCRIPTORS:

...gentamicin--drug combination--cb; gentamicin--drug therapy--dt; gentamicin--pharmacology--pd; *Haemophilus influenzae* type b vaccine --drug dose--do; *Haemophilus influenzae* type b vaccine --drug therapy--dt; *Haemophilus influenzae* type b vaccine --pharmacoconomics--pe; *Haemophilus influenzae* type b vaccine --pharmacology--pd; infusion fluid--intravenous drug administration--iv; mannitol--clinical trial--ct; mannitol--drug therapy...

MEDICAL DESCRIPTORS:

\*bacterial meningitis--drug therapy--dt; \*bacterial meningitis--etiology --et; \*bacterial meningitis-- prevention --pc; \*bacterial meningitis --therapy--th

...resistance; ataxia--side effect--si; bacterial strain; brain edema; brain hemorrhage--complication--co; brain injury-- prevention --pc; cause of death; child; childhood disease--drug therapy--dt; childhood disease--prevention --pc; clinical trial; convulsion; cost effectiveness analysis; developed country; developing country; disease severity; dose response...

...health care access; hearing loss; human; hydrocephalus--complication--co ; hypoglycemia; hypotension; hypoxia; minimum inhibitory concentration; *Neisseria meningitidis*; neurologic disease; neurological complication --complication--co; nonhuman; osmolality; penicillin resistance; review ; strain difference; *Streptococcus pneumoniae*; subdural effusion --complication--co; survival; treatment outcome

...CAS REGISTRY NO.: 1405-41-0 (gentamicin); 126161-67-9 (*Haemophilus influenzae* type b vaccine ); 69-65-8...

17/K/44 (Item 15 from file: 73)  
DIALOG(R)File 73:(c) 2008 Elsevier B.V. All rts. reserv.

The first decade of the millennium should mark the beginning of a new era

Untitled  
in vaccine development, reaping the rewards of advances in genome  
characterization, antigen identification, understanding the molecular bases

...responses, and adjuvant design and development. Advances in all of these areas have culminated in vaccine candidates entering clinical testing. These include vaccines against two of humankind's oldest and deadliest diseases, tuberculosis and malaria. Several vaccine candidates for each of these diseases will be tested in humans during the next few years. A candidate vaccine for leishmaniasis, an infection that has taught us much about T-cell regulation of protection...

**DRUG DESCRIPTORS:**

\*bacterial vaccine --drug therapy--dt; \*BCG vaccine --drug therapy--dt; \*  
BCG vaccine --pharmacology--pd; \*Leishmania vaccine --drug therapy--dt; \*  
malaria vaccine --clinical trial--ct; \*malaria vaccine --drug therapy--dt  
; \*malaria vaccine --pharmacology--pd; \*Streptococcus vaccine --drug  
therapy--dt  
...drug therapy--dt; merozoite surface protein 1--pharmacology--pd;  
recombinant protein--drug therapy--dt; recombinant vaccine --drug therapy  
--dt

**MEDICAL DESCRIPTORS:**

\*bacterial infection--drug therapy--dt; \*bacterial infection--etiology--et;  
\*bacterial infection-- prevention --pc; \*leishmaniasis--drug therapy--dt; \*  
leishmaniasis--etiology--et; \*leishmaniasis-- prevention --pc; \*malaria  
--drug therapy--dt; \*malaria--etiology--et; \*malaria-- prevention --pc; \*  
Streptococcus pneumonia--drug therapy--dt; \*Streptococcus pneumonia  
--etiology--et; \*Streptococcus pneumonia-- prevention --pc; \*tuberculosis  
--drug therapy--dt; \*tuberculosis--etiology--et; \*tuberculosis-- prevention  
--pc; \*vaccination  
animal model; cell activity; cell function; clinical trial; drug effect;  
human; infection prevention ; Leishmania; Mycobacterium tuberculosis;  
Neisseria meningitidis; nonhuman; Plasmodium falciparum; regulatory  
mechanism; review ; Streptococcus pneumoniae; T lymphocyte

17/K/45 (Item 16 from file: 73)  
DIALOG(R)File 73:(c) 2008 Elsevier B.V. All rts. reserv.

Polysaccharide (PS)-encapsulated bacteria such as *Haemophilus influenzae* type b (Hib), *Streptococcus pneumoniae* (pneumococcus), *Neisseria meningitidis* (meningococcus) and group B streptococcus (GBS), cause a major proportion of disease in early...

**DRUG DESCRIPTORS:**

\**Haemophilus influenzae* type b vaccine --drug administration--ad; \*  
*Haemophilus influenzae* type b vaccine --drug therapy--dt; \**Haemophilus influenzae* type b vaccine --intranasal drug administration--na; \*  
*Haemophilus influenzae* type b vaccine --pharmaceutics--pr; \**Meningococcus* vaccine --drug administration--ad; \**Meningococcus* vaccine --drug therapy--dt; \**Meningococcus* vaccine --intranasal drug administration--na; \*  
*Meningococcus* vaccine --pharmaceutics--pr; \**Pneumococcus* vaccine --drug administration--ad; \**Pneumococcus* vaccine --drug therapy--dt; \*  
*Pneumococcus* vaccine --intranasal drug administration--na; \**Pneumococcus* vaccine --pharmaceutics--pr; \**Streptococcus* vaccine --drug administration--ad; \**Streptococcus* vaccine --drug therapy--dt; \**Streptococcus* vaccine --intranasal drug administration--na; \**Streptococcus* vaccine

Untitled

--pharmaceutics--pr

BCG vaccine --drug therapy--dt; cholera toxin--pharmaceutics--pr;  
diphtheria toxin--pharmaceutics--pr; Escherichia coli enterotoxin  
--pharmaceutics--pr; hepatitis B vaccine --drug therapy--dt;  
immunoglobulin A--endogenous compound--ec; immunoglobulin G--endogenous  
compound--ec; immunological adjuvant--pharmaceutics--pr; lipopolysaccharide  
; oral poliomyelitis vaccine --drug administration--ad; oral poliomyelitis  
vaccine --drug therapy--dt; oral poliomyelitis vaccine --oral drug  
administration--po; oral poliomyelitis vaccine --pharmaceutics--pr; outer  
membrane protein; secretory immunoglobulin--endogenous compound--ec;  
tetanus toxoid--pharmaceutics--pr; virulence...

MEDICAL DESCRIPTORS:

\*bacterial infection--drug therapy--dt; \*bacterial infection-- prevention  
--pc; \*immunization; \*mucosal immunity; \*respiratory tract infection--drug  
therapy--dt; \*respiratory tract infection-- prevention --pc; \*vaccination  
...controlled study; CpG island; Haemophilus influenzae type b; hepatitis B  
--drug therapy--dt; hepatitis B-- prevention --pc; human; immunogenicity;  
immunological memory; infant; Neisseria meningitidis; newborn; nonhuman;  
otitis media-- prevention --pc; poliomyelitis--drug therapy--dt;  
poliomyelitis-- prevention --pc; priority journal; review ; Streptococcus  
agalactiae; Streptococcus infection--drug therapy--dt; Streptococcus  
infection-- prevention --pc; Streptococcus pneumoniae; T lymphocyte;  
tuberculosis--drug therapy--dt; tuberculosis-- prevention --pc; virus  
infection--drug therapy--dt; virus infection-- prevention --pc

CAS REGISTRY NO.: 126161-67-9 (Haemophilus influenzae type b vaccine );  
97794-27-9 (immunoglobulin G); 57425-69-1...

17/K/46 (Item 17 from file: 73)

DIALOG(R)File 73:(c) 2008 Elsevier B.V. All rts. reserv.

The successful introduction of a protein-polysaccharide conjugate  
vaccine against serogroup C meningococci into the UK infant immunization  
schedule, in combination with a catch...

...eradicating invasive meningococcal disease now seems eminently feasible.  
Since similar technology is likely to facilitate prevention of disease  
caused by serogroup A, Y and W135 meningococci, the major hurdle in  
achieving the goal of eradication is development of a safe and immunogenic  
vaccine against serogroup B infections. Outer membrane vesicle vaccines  
remain in development and further trials are anticipated. Through the  
recent availability of the meningococcal genome sequence, many new vaccine  
candidates are being identified and there is increasing optimism that a  
solution to the problem...

DRUG DESCRIPTORS:

\*glycoconjugate; \*Meningococcus vaccine --clinical trial--ct; \*  
Meningococcus vaccine --drug therapy--dt  
bacterium lipopolysaccharide; immunoglobulin G antibody--endogenous  
compound--ec; live vaccine --drug development--dv; live vaccine --drug  
therapy--dt; outer membrane protein; polysaccharide

MEDICAL DESCRIPTORS:

\*meningococciosis--diagnosis--di; \*meningococciosis--drug therapy--dt; \*  
meningococciosis--epidemiology--ep; \*meningococciosis--etiology--et; \*  
meningococciosis-- prevention --pc; \*meningococciosis--therapy--th; \*  
vaccination

Untitled

...trial; conjugate; enzyme linked immunosorbent assay; fever; fluid therapy; human; immunization; latex agglutination test; mortality; *Neisseria meningitidis*; polymerase chain reaction; priority journal; rash; review ; septicemia; serum bactericidal activity; United Kingdom

17/K/47 (Item 18 from file: 73)  
DIALOG(R)File 73:(c) 2008 Elsevier B.V. All rts. reserv.

Rational antibacterial vaccine design through genomic technologies

...benefit from the emerging genomics technologies such as bioinformatics, proteomics and DNA microarrays. In this review , the potential of these technologies will be illustrated taking into account part of the research...

...currently in progress in our laboratories. In particular, I will describe the identification of new vaccine candidates against *Meningococcus B* through high-throughput cloning and expression of meningococcal antigens selected by...

...to the elucidation of *Chlamydia pneumoniae* surface protein subproteome and to the identification of potential vaccine candidates. (c) 2003 Australian Society for Parasitology Inc. Published by Elsevier Science Ltd.

All rights...

**DRUG DESCRIPTORS:**

\*bacterial vaccine --drug therapy--dt; \**Meningococcus* vaccine --drug therapy--dt  
inactivated vaccine --drug therapy--dt; live vaccine --drug therapy--dt;  
polysaccharide vaccine --drug therapy--dt; recombinant vaccine --drug therapy--dt; subunit vaccine --drug therapy--dt; unclassified drug

**MEDICAL DESCRIPTORS:**

...bacterium isolate; *Chlamydophila pneumoniae*; clinical research; computer analysis; fluorescence activated cell sorting; genome analysis; infection prevention ; lung infiltrate--drug therapy--dt; lung infiltrate--prevention --pc; meningococcosis--drug therapy--dt; meningococcosis --etiology--et; meningococcosis-- prevention --pc; molecular cloning; *Neisseria meningitidis*; nonhuman; nucleotide sequence; pathogenesis; review ; Western blotting

**DRUG TERMS (UNCONTROLLED):** *chlamydia pneumoniae* vaccine --drug therapy--dt

17/K/48 (Item 19 from file: 73)  
DIALOG(R)File 73:(c) 2008 Elsevier B.V. All rts. reserv.

As a consequence of the general introduction of the vaccine against *Haemophilus influenzae b*, *pneumococci* (*Streptococcus pneumoniae*) together with meningococci are the most frequent cause...

...benefit of oral antibiotics is not apparent. Combinations of conjugate and polysaccharide vaccines can improve prevention strategies.

**DRUG DESCRIPTORS:**

\*antibiotic agent--drug therapy--dt; \*antibiotic agent--oral drug administration--po; \*bacterial vaccine --drug therapy--dt; \*bacterial vaccine --pharmacology--pd; \*macrolide--drug therapy--dt; \*polysaccharide

Untitled

vaccine --drug therapy--dt; \*polysaccharide vaccine --pharmacology--pd

**MEDICAL DESCRIPTORS:**

...bacterial pneumonia; combination chemotherapy; diagnostic procedure; drug efficacy; fever; Germany; human; immunoglobulin deficiency; infant; infection prevention ; infection risk; Neisseria meningitidis; nonhuman; onset age; otitis media; pathological anatomy; penicillin resistance; population risk; preschool child; prescription; review

17/K/49 (Item 20 from file: 73)

DIALOG(R)File 73:(c) 2008 Elsevier B.V. All rts. reserv.

...mutant has now been boon successfully tested in human volunteers with a trivalent subunit influenza vaccine .

**DRUG DESCRIPTORS:**

...drug combination--cb; cholera toxin--pharmacology--pd; cholera toxin B subunit--pharmacology--pd; Helicobacter pylori vaccine --clinical trial --ct; Helicobacter pylori vaccine --drug combination--cb; Helicobacter pylori vaccine --drug therapy--dt; Helicobacter pylori vaccine --oral drug administration--po; Helicobacter pylori vaccine --pharmacology--pd; hyaluronic acid; immunological adjuvant--adverse drug reaction--ae; immunological adjuvant--clinical trial--ct...

...oral drug administration--po; immunological adjuvant--pharmacology--pd; immunological adjuvant--transdermal drug administration--td; influenza vaccine --clinical trial--ct; influenza vaccine --drug combination--cb; influenza vaccine --intranasal drug administration--na; influenza vaccine --pharmacology--pd; Meningococcus vaccine --drug combination--cb; Meningococcus vaccine --drug therapy--dt; Meningococcus vaccine --pharmacology--pd; microsphere; mutant protein--adverse drug reaction--ae; mutant protein--clinical trial--ct; mutant...

...protein--drug therapy--dt; mutant protein--intranasal drug administration--na; mutant protein--pharmacology--pd; Pneumococcus vaccine --drug combination--cb; Pneumococcus vaccine --drug therapy--dt; Pneumococcus vaccine --pharmacology--pd; protein subunit; Shigella vaccine --drug combination--cb; Shigella vaccine --drug therapy--dt; Shigella vaccine --pharmacology--pd; tetanus toxoid--drug combination--cb; tetanus toxoid--drug therapy--dt; tetanus toxoid--intranasal drug administration--na; tetanus toxoid--pharmacology--pd; Toxoplasma gondii vaccine --drug combination--cb; Toxoplasma gondii vaccine --drug therapy--dt; Toxoplasma gondii vaccine --pharmacology--pd; unclassified drug

**MEDICAL DESCRIPTORS:**

...good laboratory practice; good manufacturing practice; Gram negative infection--drug therapy--dt; Gram negative infection-- prevention --pc; headache--side effect--si; heat; Helicobacter infection--drug therapy--dt; Helicobacter infection-- prevention --pc; Helicobacter pylori; human; immune response; immunogenicity; immunoregulation; inflammation--side effect--si; influenza--drug therapy--dt; influenza-- prevention --pc; meningitis; meningococcosis--drug therapy--dt; meningococcosis-- prevention --pc; Neisseria meningitidis; nonhuman; nose cavity; olfactory bulb; priority journal; regulatory mechanism; respiratory tract inflammation; review ; rhinorrhea--side effect--si; Shigella flexneri; side effect--side effect--si; site directed mutagenesis; sneezing; Streptococcus infection --drug therapy--dt; Streptococcus infection-- prevention --pc; Th1 cell;

Untitled

Th2 cell; toxicity; trachea; wild type

17/K/50 (Item 21 from file: 73)  
DIALOG(R)File 73:(c) 2008 Elsevier B.V. All rts. reserv.

...important infections, such as malaria and HIV, vaccines are not yet available. Novel strategies for vaccine development and policy implementation offer the best hope to combat the infections targeted by the

...  
**DRUG DESCRIPTORS:**

\* vaccine --drug therapy--dt; \* vaccine --pharmacoeconomics--pe  
BCG vaccine --drug therapy--dt; BCG vaccine --pharmacoeconomics--pe;  
cholera vaccine --drug therapy--dt; cholera vaccine --pharmacoeconomics  
--pe; dengue vaccine --drug therapy--dt; dengue vaccine  
--pharmacoeconomics--pe; Haemophilus influenzae type b vaccine --drug  
therapy--dt; Haemophilus influenzae type b vaccine --pharmacoeconomics--pe  
; hepatitis B vaccine --drug therapy--dt; hepatitis B vaccine  
--pharmacoeconomics--pe; Human immunodeficiency virus vaccine --drug  
therapy--dt; Human immunodeficiency virus vaccine --pharmacoeconomics--pe;  
malaria vaccine --drug therapy--dt; malaria vaccine --pharmacoeconomics  
--pe; measles vaccine --drug therapy--dt; measles vaccine  
--pharmacoeconomics--pe; Meningococcus vaccine --drug therapy--dt;  
Meningococcus vaccine --pharmacoeconomics--pe; poliomyelitis vaccine  
--drug therapy--dt; poliomyelitis vaccine --pharmacoeconomics--pe; rabies  
vaccine --drug therapy--dt; rabies vaccine --pharmacoeconomics--pe;  
Shigella vaccine --drug therapy--dt; Shigella vaccine --pharmacoeconomics  
--pe; tetanus toxoid--drug therapy--dt; tetanus toxoid--pharmacoeconomics  
--pe; typhoid vaccine --drug therapy--dt; typhoid vaccine  
--pharmacoeconomics--pe

**MEDICAL DESCRIPTORS:**

\*diphtheria--drug therapy--dt; \*diphtheria--epidemiology--ep; \*diphtheria--  
prevention --pc; \*measles--drug therapy--dt; \*measles--epidemiology--ep; \*  
measles-- prevention --pc; \*newborn tetanus--drug therapy--dt; \*newborn  
tetanus--epidemiology--ep; \*newborn tetanus-- prevention --pc; \*pertussis  
--drug therapy--dt; \*pertussis--epidemiology--ep; \*pertussis-- prevention  
--pc; \*poliomyelitis--drug therapy--dt; \*poliomyelitis--epidemiology--ep; \*  
poliomyelitis-- prevention --pc; \*tuberculosis--drug therapy--dt; \*  
tuberculosis--epidemiology--ep; \*tuberculosis--etiology--et; \*tuberculosis  
-- prevention --pc; \*vaccination  
acute diarrhea--drug therapy--dt; acute diarrhea--epidemiology--ep; acute  
diarrhea-- prevention --pc; bacterial infection--drug therapy--dt;  
bacterial infection--epidemiology--ep; bacterial infection--etiology--et;  
bacterial infection-- prevention --pc; cause of death; cholera--drug  
therapy--dt; cholera--epidemiology--ep; cholera--etiology--et; cholera--  
prevention --pc; dengue--drug therapy--dt; dengue--epidemiology--ep; dengue  
-- prevention --pc; drug cost; drug effect; Enterobacter infection--drug  
therapy--dt; Enterobacter infection--epidemiology--ep; Enterobacter  
infection--etiology--et; Enterobacter infection-- prevention --pc; epidemic  
encephalitis--drug therapy--dt; epidemic encephalitis--epidemiology--ep;  
epidemic encephalitis--etiology--et; epidemic encephalitis-- prevention  
--pc; Escherichia coli; Flavivirus; Haemophilus influenzae type b; health  
program; hepatitis B--drug therapy--dt; hepatitis B--epidemiology--ep;  
hepatitis B-- prevention --pc; human; Human immunodeficiency virus  
infection--epidemiology--ep; immunotherapy; malaria--drug therapy--dt;

Untitled

malaria--epidemiology--ep; malaria-- prevention --pc; meningitis--drug therapy--dt; meningitis--epidemiology--ep; meningitis--etiology--et; meningitis-- prevention --pc; Mycobacterium tuberculosis; Neisseria meningitidis; pneumonia--drug therapy--dt; pneumonia--epidemiology--ep; pneumonia-- prevention --pc; prevalence; priority journal; rabies--drug therapy--dt; rabies--epidemiology--ep; rabies-- prevention --pc; review ; Rotavirus; Salmonella typhi; Shigella dysenteriae; Shigella flexneri; Shigella sonnei; treatment outcome; tropics; typhoid fever--drug therapy --dt; typhoid fever--epidemiology--ep; typhoid fever--etiology--et; typhoid fever-- prevention --pc; Vibrio cholerae; virus infection--drug therapy--dt ; virus infection--epidemiology--ep; virus infection--etiology--et; virus infection-- prevention --pc; world health organization; Yellow fever  
flavivirus

CAS REGISTRY NO.: 126161-67-9 (Haemophilus influenzae type b vaccine );  
57425-69-1...

? T S17/3/21,23,25,26,27,13,46,42,40,35,34

17/3/21 (Item 5 from file: 34)

DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

(c) 2008 The Thomson Corp. All rts. reserv.

10674586 Genuine Article#: 555BV No. References: 93

Title: Meningococcal disease: how to prevent and how to manage

Author(s): Balmer P; Miller E (REPRINT)

Corporate Source: Ctr Communicable Dis Surveillance, Publ Hlth Lab Serv, Div Immunizat, 61 Colindale Ave/London NW9 5EQ//England/ (REPRINT); Ctr Communicable Dis Surveillance, Publ Hlth Lab Serv, Div Immunizat, London NW9 5EQ//England/

Journal: CURRENT OPINION IN INFECTIOUS DISEASES, 2002, V15, N3 (JUN), P 275-281

ISSN: 0951-7375 Publication date: 20020600

Publisher: LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA

Language: English Document Type: REVIEW (ABSTRACT AVAILABLE)

17/3/23 (Item 7 from file: 34)

DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

(c) 2008 The Thomson Corp. All rts. reserv.

10307308 Genuine Article#: 510QM No. References: 86

Title: Vaccines against meningococcal disease: current and future technologies

Author(s): Riddell A (REPRINT) ; Buttery J

Corporate Source: John Radcliffe Hosp, Oxford Vaccine Grp, Level 4/Oxford OX3 9DU//England/ (REPRINT); John Radcliffe Hosp, Oxford Vaccine Grp, Oxford OX3 9DU//England/

Journal: EXPERT OPINION ON BIOLOGICAL THERAPY, 2001, V1, N3 (MAY), P385-399

ISSN: 1471-2598 Publication date: 20010500

Publisher: ASHLEY PUBLICATIONS LTD, UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND

Language: English Document Type: REVIEW (ABSTRACT AVAILABLE)

17/3/25 (Item 1 from file: 45)

Untitled

DIALOG(R)File 45:EMCare  
(c) 2008 Elsevier B.V. All rts. reserv.

00607560 EMCare No: 29218222

Prevention and management of overwhelming postsplenectomy infection -

An update

Brigden M.L.; Pattullo A.L.

Dr. M.L. Brigden, Department of Medical Oncology, BC Cancer Agency,  
Center for the Southern Interior, Kelowna, BC Canada

Critical Care Medicine ( CRIT. CARE MED. ) (United States) 1999, 27/4  
(836-842)

CODEN: CCMDC ISSN: 0090-3493

DOCUMENT TYPE: Journal ; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 46

RECORD TYPE: Abstract

Copyright 2006 Elsevier B.V., All rights reserved.

17/3/26 (Item 2 from file: 45)

DIALOG(R)File 45:EMCare  
(c) 2008 Elsevier B.V. All rts. reserv.

00440097 EMCare No: 28151953

Bacterial meningitis and meningococcal infection

Booy R.; Kroll J.S.

R. Booy, Department of Pediatrics, Imperial College School Medicine, St  
Mary's Hospital, Norfolk Place, London W2 1PG United Kingdom

Current Opinion in Pediatrics ( CURR. OPIN. PEDIATR. ) (United States)  
1998, 10/1 (13-18)

CODEN: COPEE ISSN: 1040-8703

DOCUMENT TYPE: Journal ; Review

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 60

RECORD TYPE: Abstract

Copyright 2006 Elsevier B.V., All rights reserved.

17/3/27 (Item 3 from file: 45)

DIALOG(R)File 45:EMCare  
(c) 2008 Elsevier B.V. All rts. reserv.

00356754 EMCare No: 27464039

Immunological behavior of the meningococcal vaccines

COMPORTAMENTO IMUNOLOGICO DAS VACINAS ANTI-MENINGOCOCICAS

Requejo H.I.Z.

H.I.Z. Requejo, Av. Dr. Arnaldo, 355, 01246-901 Sao Paulo, SP Brazil

Revista de Saude Publica ( REV. SAUDE PUBLICA ) (Brazil) 1997, 31/4  
(402-416)

CODEN: RSPUB ISSN: 0034-8910

DOCUMENT TYPE: Journal ; Review

LANGUAGE: PORTUGUESE SUMMARY LANGUAGE: PORTUGUESE; ENGLISH

NUMBER OF REFERENCES: 100

RECORD TYPE: Abstract

Copyright 2006 Elsevier B.V., All rights reserved.

Untitled

17/3/13 (Item 13 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

12179746 BIOSIS NO.: 199497201031  
Advances in biology, management and prevention of infections caused by  
Chlamydia trachomatis and Neisseria gonorrhoeae  
AUTHOR: Kihlstrom Erik; Danielsson Dan  
AUTHOR ADDRESS: Dep. Clin. Microbiol. Immunol., Orebro Med. Cent. Hosp.,  
S-701 85 Orebro, Sweden\*\*Sweden  
JOURNAL: Current Opinion in Infectious Diseases 7 (1): p25-33 1994 1994  
ISSN: 0951-7375  
DOCUMENT TYPE: Article; Literature Review  
RECORD TYPE: Citation  
LANGUAGE: English

17/3/46 (Item 17 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0079524562 EMBASE No: 2003230842  
Meningococcal vaccines  
Bethell D.; Pollard A.J.  
Department of Paediatrics, University of Oxford, John Radcliffe Hospital,  
Oxford OX3 9DU, United Kingdom  
AUTHOR EMAIL: andrew.pollard@paediatrics.ox.ac.uk  
CORRESP. AUTHOR: Pollard A.J.  
CORRESP. AUTHOR AFFIL: Department of Paediatrics, University of Oxford,  
John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom  
CORRESP. AUTHOR EMAIL: andrew.pollard@paediatrics.ox.ac.uk

Expert Review of Vaccines ( Expert Rev. Vaccines ) (United Kingdom) June  
1, 2002, 1/1 (75-84)  
CODEN: ERVXA ISSN: 14760584  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 97

17/3/42 (Item 13 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0079623722 EMBASE No: 2003331776  
Neisseria meningitidis serogroup A vaccines: An overview  
Heath P. // Vergnano S.  
Department of Child Health, St. George's Hospital Medical School, Cranmer  
Terrace, London SW17 ORE, United Kingdom // International Perinatal Unit,  
Institute of Child Health, 30 Guildford St, London WC1N 1E4, United  
Kingdom  
AUTHOR EMAIL: pheath@sghms.ac.uk; svergnano@hotmail.com  
CORRESP. AUTHOR: Heath P.

Untitled

CORRESP. AUTHOR AFFIL: Department of Child Health, St. George's Hospital Medical School, Cranmer Terrace, London SW17 ORE, United Kingdom  
CORRESP. AUTHOR EMAIL: pheath@sghms.ac.uk

Expert Review of Vaccines ( Expert Rev. Vaccines ) (United Kingdom)

August 1, 2003, 2/4 (571-582)

CODEN: ERVXA ISSN: 14760584

DOI: 10.1586/14760584.2.4.571

DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 60

17/3/40 (Item 11 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0079715586 EMBASE No: 2003425099

Meningococcal serogroup B infections: A search for a broadly protective vaccine

Vermont C.L. // Vermont C.L.; Van den Doppelstein G.P.J.M.  
Erasmus MC/Sophia Children's Hosp., Department of Pediatrics, Div.  
Pediat. Infect. Dis./Immunol., PO Box 2060, 3000 CB Rotterdam,  
Netherlands // Netherlands Vaccine Institute, Laboratory for Vaccine  
Research, Bilthoven, Netherlands

AUTHOR EMAIL: c.vermont@erasmusmc.nl; c.vermont@erasmusmc.nl

CORRESP. AUTHOR: Vermont C.L.

CORRESP. AUTHOR AFFIL: Erasmus MC/Sophia Children's Hosp., Department of  
Pediatrics, Div. Pediat. Infect. Dis./Immunol., PO Box 2060, 3000 CB  
Rotterdam, Netherlands

CORRESP. AUTHOR EMAIL: c.vermont@erasmusmc.nl

Expert Review of Vaccines ( Expert Rev. Vaccines ) (United Kingdom)

October 1, 2003, 2/5 (673-681)

CODEN: ERVXA ISSN: 14760584

DOI: 10.1586/14760584.2.5.673

DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 68

17/3/35 (Item 6 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0079825800 EMBASE No: 2004010566

Meningococcal immunology

Lepow M.L.; Hughes P.A.

Division of Infectious Diseases, Department of Pediatrics, Albany Medical Center, 47 New Scotland Avenue, Albany, NY 12208, United States

AUTHOR EMAIL: LepowM@mail.ame.edu

CORRESP. AUTHOR: Lepow M.L.

CORRESP. AUTHOR AFFIL: Division of Infectious Diseases, Department of Pediatrics, Albany Medical Center, 47 New Scotland Avenue, Albany, NY 12208, United States

Untitled

CORRESP. AUTHOR EMAIL: LepowM@mail.ame.edu

Immunology and Allergy Clinics of North America ( Immunol. Allergy Clin. North Am. ) (United States) November 1, 2003, 23/4 (769-786)

CODEN: INCAE ISSN: 08898561

DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 90

17/3/34 (Item 5 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0079962269 EMBASE No: 2004147292

Vaccines: State of the art

Novedades en vacunas

Cofre G. J.

Unidad de Infectologia, Servicio de Pediatría, Hospital Luis Calvo

Mackenna

CORRESP. AUTHOR AFFIL: Unidad de Infectologia, Servicio de Pediatría,  
Hospital Luis Calvo Mackenna

Revista Chilena de Pediatría ( Rev. Chil. Pediatr. ) (Chile) July 1, 2003, 74/4 (366-373)

CODEN: RCPEA ISSN: 03704106

DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract

LANGUAGE: Spanish SUMMARY LANGUAGE: English; Spanish

NUMBER OF REFERENCES: 50

? DS

Set Items Description

S1 1 AU='FEYT, R. P.'

S2 2 AU='FEYT, R.'

S3 2 RD (unique items)

S4 3 AU='NIETO, G.' OR AU='NIETO, GERARDO GUILLEN'

S5 3 RD (unique items)

S6 1 AU='NUNEZ LAZARO HIRAM BETANCOURT'

S7 19 AU='BLANCO, SONIA' OR AU='BLANCO, SONIA E.'

S8 19 RD (unique items)

S9 103921 NEISSERIA

S10 0 S7 AND S9

S11 3855735 PREVENT OR PREVENTION

S12 9266 S9 AND S11

S13 710632 VACCINE

S14 3715 S12 AND S13

S15 735 S14 AND REVIEW

S16 593 RD (unique items)

S17 306 S16 NOT PY>2003

? LOGOFF

22jan08 10:59:30 User294085 Session D165.2